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ABSTRACT
DEVELOPMENT OF A HIGH THROUGHPUT ASSAY TO OPTIMIZE
HEMATOPOIETIC DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS
Joel Thomas Outten
Advisor: Scott L. Diamond
Human embryonic stem cells (hESCs) offer the potential to develop in vitro
protocols for the generation of any human somatic cell. In order for protocols to allow
for both comprehension of underlying developmental mechanics and future clinical
application, they will need to rely upon efficient differentiation of cells without the
reliance upon animal-derived components. This thesis presents the development of a 96well plate culture system that allows 4-color, flow cytometry based high throughput
screening of defined, serum-free hESC differentiation conditions. In the first portion,
broad applicability is proven by demonstrating highly efficient differentiation toward the
three primary germ layers. Using four separate biomarkers, we were able to distinguish
between ectoderm, endoderm, mesoderm and pluripotent hESCs.

We demonstrated the

ability to perform both cytokine screens and siRNA-mediated knockdown in this assay.
In the second portion, we establish conditions to apply this assay to study hematopoietic
differentiation. We performed numerous cytokine and inhibitor screens to develop a
stepwise protocol that generates high yields of primitive megakaryocyte-erythromyeloid
progenitors and megakaryocytes after 8 and 11 days of embryoid body differentiation,
respectively. This work provides a novel tool to streamline the development of hESC
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differentiation protocols and advances the hematopoietic field towards future hESCderived therapies.
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1.

Introduction

1.1

Human embryonic stem cells
The isolation of human embryonic stem cells (hESCs) in 1998 [1] has

revolutionized the field of regenerative medicine.

hESCs, isolated from human

blastocysts, exhibit pluripotency and can thus be theoretically induced to generate any
somatic human cell. These cells offer new approaches to study human development and
organogenesis, screen candidate drug molecules for toxicities, treat previously incurable
pathologies, generate lines of desired cell types, and study disease mechanisms. Studies
are increasingly being undertaken in all of these areas. While these cells have vast
scientific and medical potential, progress relies on scientists to identify repeatable
techniques to control differentiation outcome. Initial studies identified basic conditions
to differentiate cells to the three primary germ layers [2, 3]. Somatic adult cells, in
contrast, require lengthy differentiation pathways that must be tightly controlled and are
infrequently understood. Increasingly more studies focus on defining protocols by which
to differentiate hESCs to target cell lineages.

1.2

Mammalian development
hESCs are extracted from the inner cell mass of the approximately 6 day old

blastocyst [3]. In mammalian development, the inner cell mass develops into the epiblast
within a few days. The onset of gastrulation is marked by the formation of the primitive
streak on the surface of the epiblast around day 14. Epiblast cells begin to migrate
1

through the primitive streak and differentiate into either mesoderm or definitive
endoderm. Epiblast cells that do not migrate through the streak will form the ectoderm.
These three germ layers eventually differentiate into all the cells and tissues of the body
[4].
Gastrulation, as well as the entire process of development, is a highly coordinated,
delicate interplay of growth factors and cytokines secreted and received at just the right
moments.

The primitive streak itself is initiated by coordinated expression of the

transforming growth factor-beta (TGF-b) family members Nodal and bone morphogenic
protein 4 (BMP4) and members of the Wnt family. The local concentration of these
growth factors induces streak cells to migrate and begin differentiating toward the
mesoderm and endoderm lineages. The extraembryonic endoderm secretes BMP4 during
gastrulation. A BMP4 diffusion gradient is thus formed in which posterior primitive
streak cells receive the highest exposure and anterior cells receive the lowest. BMP4
promotes mesoderm, inducing posterior streak cells to differentiate down this lineage.
Conversely, high concentrations of Nodal, secreted by the node by late-streak stage,
promote anterior streak cells to become definitive endoderm. Members of the fibroblast
growth factor (FGF) family, including FGF4 and FGF8, are also required for primitive
streak formation and gastrulation. The signaling pathways utilized during development
are thoroughly reviewed in Gadue et al. [5] and Murry and Keller [6].
In vitro experiments aim to recapitulate hESC development by mimicking the in
vivo environment. Developmental signals and cues in vivo can be utilized to structure
differentiation protocols of hESCs.

Therefore, studies aim to follow developmental

principles and pathways when differentiating to various lineages. Conversely, hESC
2

studies can help elucidate pathways and developmental mechanisms to give a greater
understanding of in vivo embryogenesis.

1.3

Differentiation systems
Although scientists frequently know what target cell they aim to generate, the

most appropriate path of differentiation is generally more elusive.

Three primary

methods have been utilized to support differentiation systems: 1) embryoid body (EB)
suspension culture, 2) adherent culture, and 3) co-culture with another cell line.
Although the technique of choice depends upon the goal, the vast majority of studies
have relied upon EB culture, and many protocols incorporate multiple methods.

1.3.1 Embryoid body culture
When undifferentiated hESCs are seeded in suspension (generally as clumps of
cells), cells aggregate and form spherical three-dimensional clusters called embryoid
bodies. Depending on external signaling cues, cells within EBs differentiate to one of the
three primary germ layers as the EBs increase in size during differentiation. EBs are
generally cultured in one of four systems: 1) hanging drops 2) liquid suspension culture
3) methylcellulose medium, and 4) large-scaleable bioreactors [7]. Each method carries
advantages and disadvantages. As a general principle, studies have shown that results are
more reliable, dependable, and controllable when homogenous EBs of known sizes are
utilized .

3

Hanging Drops
Although becoming less common, hanging drops have traditionally been widely
used as a reliable method of generating consistent EBs of known size[8]. Individual
drops of medium containing cells at a known density are attached to the underside of a
plastic petri dish lid. Cells aggregate in the rounded bottom of each drop and form an EB
of defined cell number. This method is becoming less common due to the time required
to seed and harvest EBs.

Liquid suspension culture
Many studies have relied on seeding single cells or clumps of ESCs into 6 to 24well culture plates. EBs are formed either from spontaneous aggregation or from nondissociated clusters of cells [2, 9]. Due to the uncontrolled environment, EBs tend to be
heterogenous in these systems[7]. EBs also have the potential to aggregate together
during differentiation [10].

Rotary culture of EBs during differentiation has been

demonstrated to induce homogenous EBs and increase yield and differentiation
efficiency, albeit through an unknown mechanism [11].

More recently, groups have

utilized micro-scale conical-patterned well inserts to generate hundreds of thousands of
EBs from centrifugation of cells prior to seeding EBs in liquid suspension differentiation
culture [12]. Similar technologies are now commercially available.

Methylcellulose culture
Semisolid methylcellulose culture has been utilized to avoid uncontrolled
aggregation and ensure the formation of single cell-derived EBs [13]. This method has
4

been used mostly for hematopoietic differentiation, but has become less frequent due to
the difficulty of harvesting cells from methylcellulose.

Large scale bioreactors
Many commercial and therapeutic applications of ESC protocols will require
extremely large amounts of cells, negating the reliance on standard cell culture systems.
Bioreactor systems can be scaled to meet such demands. As with liquid culture systems,
multiple EBs can aggregate in such systems, reducing the homogeneity of EB
populations. In order to minimize this phenomenon, EB formation is completed ahead of
time, for instance in hanging drops[14], and then transferred to bulk stirred suspension
cultures.

1.3.2 Adherent and stromal cell co-culture
While EB culture supports ESC differentiation toward numerous lineages, several
alternative approaches have been utilized to re-create a more developmentally-realistic
stem cell niche. Both adherent and stromal cell co-culture aim to accomplish this goal.
Adherent methods entail culturing ESCs as a two-dimensional monolayer on extracellular
matrix proteins and allow for more control and generally exhibit less variability than EB
protocols. However, such protocols can not be scaled-up to bioreactor culture and have
only been demonstrated to be applicable for a small number of differentiation pathways.
Numerous animal stromal cells have been demonstrated to induce efficient
differentiation. Stromal cells derived from the murine aorta-gonad-mesonephros (AGM),

5

the fetal liver, and the bone marrow have all been utilized to efficiently differentiate
ESCs towards the hematopoietic lineage [15].

1.4

Serum-free differentiation media
Early ESC protocols relied on the use of serum containing media due to the

enhanced viability and efficient differentiation [1, 16-18]. However, serum contains a
plethora of unknown factors, is significantly variable between lots, and is not clinically
applicable. To overcome these limitations, more recent feeder-free studies have focused
on identifying serum-free media formulations [19-21].

Numerous combinations of

cytokines, growth factors, and siRNA molecules are being evaluated in order to
understand signaling pathways utilized during differentiation and to optimize
differentiation protocols to target cell types. By precisely activating or inhibiting the
TGFb family, FGF, Wnt, and other pathways at specific times, the developing embryo
directs differentiation to all somatic cells of the body [5]. In vitro hESC differentiation
systems attempt to recapitulate these developmental pathways by utilizing controlled
concentrations of cytokines and inhibitors. As differentiation proceeds down specific
lineages, the possible number of cytokine combinations dramatically increases.

1.5

Small scale platforms
In an effort to reduce the requisite time and materials needed to assess a large

array of conditions and cytokine combinations, several groups have developed small6

scale culture platforms. Ng et al. have developed a 96-well spin embryoid body (EB)
technique in which hESCs are spun down to form a single EB of a defined size within
each well [22, 23]. This technique has been utilized to optimize differentiation to various
stages in the hematopoietic lineage[24, 25]. Koike et al. have developed a 96-well
murine ESC (mESC) differentiation system and explored effects of EB seeding density
upon differentiation to cardiomyocytes [26, 27]. Both of these systems allow for a high
degree of control over the medium environment, enabling precise identification of
extrinsic factors that may influence EB differentiation.

However, due to the small

seeding density utilized by both methods to generate single EBs and the tendency for cell
counts to drop over the first five days of differentiation [24], it is unclear if enough cells
would be available for readouts such as 96-well flow cytometry analyses without pooling
wells. Furthermore, these systems cannot be scaled up to larger platforms, limiting the
number of EBs that can be produced. Several studies have utilized an adherent 384-well
plate format to screen for small molecule inhibitors or enhancers of ESC differentiation
[28, 29]. Although these confocal microscopy-based assays have been utilized to screen
several thousand small molecules, they are not conducive to multi-color flow-cytometry
or live cell sorting and would only be applicable to adherent culture protocols.

7

2.

Materials and Methods

2.1

hESC maintenance
HES2 (passage 26-34) and H9 cells (passage 35-65) were maintained on

irradiated mouse embryonic fibroblasts (MEFs) in hESC maintenance medium consisting
of DMEM/F12 50:50 (Mediatech) supplemented with 20% Knockout Serum (Invitrogen,
Carlsbad, CA), 1x non-essential amino acids (Invitrogen), 0.55 mM b-mercaptoethanol,
1% penicillin/streptomycin, 2 mM glutamine (Invitrogen), and 20 ng/mL bFGF (R&D
Systems, Minneapolis, MN).

Cells were passaged at 1:3-1:6 ratios using 0.25%

trypsin/EDTA (Mediatech, Manassas, VA) or TrypLE Express (Invitrogen). For siRNA
experiments, a previously established HES2 line was utilized that expresses a red
fluorescent protein (RFP) from the hROSA26 locus (HES2-R26) [30].

2.2

hESC differentiation

2.2.1 Germ layer differentiation
A 6-day differentiation procedure was utilized (Fig. 3.1A).

Prior to

differentiation, hESCs were trypsinized and replated on matrigel (Becton Dickinson,
Franklin Lakes, NJ) in hESC maintenance medium. Serum-free differentiation (SFD)
medium consisted of 75% IMDM (Invitrogen), 25% F12 (Mediatech), 0.5x N-2
supplement (Invitrogen) 0.5x B27 without retinoic acid (Invitrogen), and 0.05% BSA
(Sigma, St. Louis, MO). Upon 75% confluency, cells were trypsinized, harvested with a
8

cell scraper, spun down, and resuspended in SFD medium supplemented with
penicillin/streptomycin, 2 mM glutamine, 0.5 mM ascorbic acid (Sigma), 1.5x10-4 M
monothioglycerol (Sigma), and the specified concentrations of cytokines as indicated
(summarized in Table 2.1). Day 0 media was supplemented with: 10 ng/mL BMP4
(R&D Systems) for endoderm/mesoderm or 10 mM SB431542 (Tocris, Ellisville, MO),
500 ng/mL BMPR1A (R&D Systems), and 5 ng/mL bFGF (R&D Systems, Minneapolis,
MN) for ectoderm. 2x106 cells were seeded into 10-cm petri dishes and cultured at 5%
CO2/5% O2/90% N2. After 24 hours, EBs were harvested, manually disrupted, and
seeded into 100 mL Day 1 medium into low-cluster 96-well plates (Corning, Corning,
NY) at 2x105 cells/mL (2x104 cells/well). Endoderm Day 1 medium was supplemented
with 100 ng/mL activin A (R&D Systems), 2.5 ng/mL bFGF, 0.5 ng/mL BMP4.
Mesoderm Day 1 medium was supplemented with 0.5 ng/mL activin A, 2.5 ng/mL bFGF,
and 20 ng/mL BMP4. Ectoderm Day 1 medium was supplemented with 5 ng/mL bFGF,
10 mM SB431542, and 500 ng/mL BMPR1A. For growth factor screening experiments,
Day 1 media contained 2.5 ng/mL bFGF, and activin A and BMP4 were utilized at
concentrations of 0 to 100 ng/mL, as indicated. At Day 4, 200 mL of Day 4 media were
added to each well. Day 4 mesoderm and endoderm media were identical to Day 1
media, but with 5 ng/mL bFGF. Day 4 ectoderm medium was identical to Day 1 medium
with 20 ng/mL bFGF.

For growth factor screening experiments, media were

supplemented with 5 ng/mL bFGF, the indicated concentrations of activin A and BMP4,
and ± 10 ng/mL VEGF165 (R&D Systems). During incubation, 96-well plates were
covered with gas-permeable membranes (Breathe Easy, Diversified Biotech, Boston,
MA) and stainless steel plate lids (Kalypsys, Inc., San Diego, CA).
9

Table 2.1. Differentiation media for germ layer induction
Day 0

Day 1

Day 4

Endoderm

•2 mM Glutamine
(Invitrogen)
•0.5 mM ascorbic acid
(Sigma)
•1.5x10-4 M
monothioglycerol (Sigma)
•10 ng/mL BMP4 (R&D
Systems)

•2 mM Glutamine
•0.5 mM ascorbic acid
•1.5x10-4 M
monothioglycerol
•0.5 ng/mL BMP4
•100 ng/mL Activin A
•5 ng/mL bFGF

Mesoderm

Identical to Day 0 endoderm

Ectoderm

•2 mM Glutamine
•0.5 mM ascorbic acid
•1.5x10-4 M
monothioglycerol
•500 ng/mL BMPR1A
(R&D Systems)
•10 mM SB431542 (Tocris)
•5 ng/mL bFGF

•2 mM Glutamine
•0.5 mM ascorbic acid
•1.5x10-4 M
monothioglycerol
•0.5 ng/mL BMP4
•100 ng/mL Activin A
(R&D Systems)
•2.5 ng/mL bFGF (R&D
Systems)
•2 mM Glutamine
•0.5 mM ascorbic acid
•1.5x10-4 M
monothioglycerol
•20 ng/mL BMP4
•0.5 ng/mL Activin A
•2.5 ng/mL bFGF
Identical to Day 0 ectoderm

•2 mM Glutamine
•0.5 mM ascorbic acid
•1.5x10-4 M
monothioglycerol
•20 ng/mL BMP4
•0.5 ng/mL Activin A
•5 ng/mL bFGF
•2 mM Glutamine
•0.5 mM ascorbic acid
•1.5x10-4 M
monothioglycerol
•500 ng/mL BMPR1A
•10 mM SB431542
•20 ng/mL bFGF

2.2.2 Hematopoietic differentiation
Cells were harvested from matrigel upon reaching 70-80% confluency by
enzymatic cleavage with TrypLE Express for 4 min at RT. Cells were removed with a
cell scraper, spun down at 1200 rpm for 3 min, and resuspended in differentiation buffer.
Differentiation medium consisted of StemPro-34 serum-free medium (SP34 SFM;
Invitrogen) supplemented with penicillin/streptomycin, 2 mM glutamine, 0.5 mM
ascorbic acid, 1.5x10-4 M monothioglycerol, and growth factors and inhibitors as
specified in Results. Resuspended cell clusters were partially disrupted by pipetting up
and down 3-4 times with a serological pipet. Depending upon experiment, the following
cytokines and inhibitors were added at specified concentrations at designated stages of
10

differentiation as described in Results: 0-40 ng/mL BMP4, 0-100 ng/mL VEGF, 5-10
ng/mL bFGF, TPO, Flt3-L, IL-3, IL-6 (all R&D Systems), Chir-99021 (Stemgent), and
Y-27632 (Tocris).

Cells were seeded at 20,000 cells/well into 96-well ultra-low

attachment plates.

To isolate day 7 single cells for further differentiation and

methylcellulose cultures, wells were pooled and EBs allowed to settle for several
minutes.

Supernatant was then withdrawn to extract single cells.

For further

hematopoietic differentiation, single cells were transferred to 6-well ultra-low adherence
plates and cultured in SP34 based medium supplemented with penicillin/streptomycin, 2
mM glutamine, 0.5 mM ascorbic acid, 1.5x10-4 M monothioglycerol, 50 ng/mL SCF, 100
ng/mL TPO, 2 U/mL EPO, 25 ng/mL Flt3-L, 10 ng/mL IL-6, and 10 ng/mL IL-3.

2.3

96-well flow cytometry

2.3.1 Germ layer differentiation
EBs were dissociated, stained, and analyzed via 96-well flow cytometry as
described [31].

EBs were transferred to 96-well V-bottom plates, spun down, and

dissociated with 0.25% trypsin/EDTA. Antibodies utilized were: rat anti-SSEA-3-Alexa
488 (Biolegend, San Diego, CA, 330306), mouse anti-CXCR4-PE (Invitrogen,
MHCCXCR404), mouse anti-NCAM-PE/Cy7 (Biolegend, 318318), mouse anti-KDRAlexa 647 (Biolegend, 338909), mouse anti-PDGFRa-biotin (Biolegend, 323503), and
streptavidin-PE/Cy7 (Invitrogen, SA1012). Cells were acquired directly from 96-well
plates using a C6 Flow Cytometer equipped with a 96-well plate C-Sampler (Accuri, Ann
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Arbor, MI) and analyzed using CFlow Plus software (Accuri) or FlowJo (Treestar,
Ashland, OR). Markers utilized for flow cytometry are given in Table 2.2.
Table 2.2. Extracellular markers used for flow cytometry analyses
Extracellular marker
KDR (kinase insert
domain receptor)

Alternative names
VEGFR2, FLK1, CD309

SSEA-3 (stage-specific
antigen 3)
CXCR4 (chemokine C-XC motif receptor 4)
NCAM (neural cell
adhesion molecule)

NCAM1, CD56

PDGFRa (platelet-derived
growth factor receptor a)

CD140a

CD31

PECAM-1
(platelet/endothelial cell
adhesion molecule)

CD34
CD43

sialophorin

CD41

CD41B, GP aIIb, integrin
aIIb

CD42a

GP IX (glycoprotein IX)

CD235a

GYPA (glycophorin A)

CD45

PRPRC (protein tyrosine
phosphatase, receptor type
C)
ITGB2 (integrin beta 2)

CD18

Expression
Many mesoderm
subpopulations and on
pluripotent stem cells.
Pluripotent stem cells and
early ectoderm.
Expression decreases with
advanced differentiation.
Endoderm and certain
mesoderm subpopulations.
Early ectoderm and many
endoderm and mesoderm
subpopulations.
Mesoderm subpopulations.
Indicative of paraxial
commitment in murine
stem cell differentiation.
Hematopoietic and
endothelial cells.
Many hematopoietic
populations.
Many hematopoietic
populations.
Megakaryocyte
progenitors and committed
megakaryocytes.
Committed
megakaryocytes.
Erythrocyte progenitors
and committed
erythrocytes.
Mature hematopoietic and
myeloid cells.
Myeloid cells.
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2.3.2 Hematopoietic differentiation
EBs were dissociated with either 0.25% trypsin/EDTA or with Collagenase B
(Roche) followed by Accutase (Invitrogen). Antibodies utilized were: rat anti-SSEA-3Alexa 488, mouse anti-KDR-Alexa 647 (Biolegend), mouse anti-CD31 PE/Cy7
(Biolegend), mouse anti-CD34 Alexa 488 (Biolegend), mouse anti-CD43 FITC
(Biolegend), mouse anti-CD43 PE (Biolegend), mouse anti-CD41 APC (Biolegend),
mouse anti-CD41 PE (Biolegend), mouse anti-CD42a PE (BD Pharmingen), mouse antiCD45 PE/Cy7 (Biolegend), and mouse anti-CD235a APC (BD Pharmingen). Cells were
analyzed with 96-well flow cytometry as discussed previously.

2.4

Real-time quantitative PCR
EBs were collected from wells and dissociated with 0.25% trypsin/EDTA. Cells

were lysed with the facilitation of QiaShredder columns and RNA was harvested using an
RNeasy Mini-kit and treated with RNase-free DNase (Qiagen, Valencia, CA). Reverse
transcription was performed with the iScript cDNA synthesis kit (Bio-rad, Hercules, CA)
or the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Real-time
quantitative PCR (qPCR) was performed in triplicate on a Roche Lightcycler 480 using
LightCycler 480 SYBR Green I master mix (Roche, Indianapolis, IN) and 500 nM primer
concentrations (Table 2.3).

All gene expression levels were normalized to the

housekeeping gene GAPDH [24].
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Table 2.3. Primers utilized for real-time quantitative PCR analysis
Gene
OCT4
NANOG
GSC
SOX17
FOXA2
CXCR4
CER1
Brachyury
KDR
PDGFRa
PDGFRb
MEOX1
PAX6
SOX1
Nestin
NCAM
CD34
RFP

2.5

Sequence
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse

GCAAAACCCGGAGGAGTC
CCACATCGGCCTGTGTATATC
ATGCCTCACACGGAGACTGT
AGGGCTGTCCTGAATAAGCA
ACCTCCGCGAGGAGAAAG
GTTCCACTTCTCCGCGTTC
CGCCGAGTTGAGCAAGAT
GGTGGTCCTGCATGTGCT
CCGTTCTCCATCAACAACCT
GCCTTGAGGTCCATTTTGTG
CTGTGAGCAGAGGGTCCAG
ATGAATGTCCACCTCGCTTT
GGGAGACCTGCAGGACAGT
CAGGAGGTATGGGAGTGCTG
TTCAAGGAGCTCACCAATGA
GAAGGAGTACATGGCGTTGG
CAGGATGCAGAGCAAGGTG
TCAAGAGAAACACTAGGCAAACC
CCACCTGAGTGAGATTGTGG
TCTTCAGGAAGTCCAGGTGAA
AGGCTGGCCACTACACCAT
AGCACTCGGACAGGGACAT
AAATCATCCAGGCGGAGAA
AAGGCCGTCCTCTCCTTG
CAAATAACCTGCCTATGCAACC
TAACTCCGCCCATTCACC
CAGGCCATGGATGAAGGA
CTTAATTGCTGGGGAATTG
GAGGTGGCCACGTACAGG
AAGCTGAGGGAAGTCTTGGA
CTGCATTGCTGAGAACAAGG
CATATGTGATTTTGGGTTTTGC
GCGCTTTGCTTGCTGAGT
GGGTAGCAGTACCGTTGTTGT
CTGAAGGGCGAGATCCAC
TGGCCATGTAGATGGTCTTG

Amplicon
Length
113
66
107
113
89
60
142
108
93
83
91
95
94
65
86
80
67
82

siRNA knockdown
HES2 cells stably expressing RFP (HES2-R26 cells) [30] were reverse transfected

at the time of 96-well plate seeding at Day 1. 2x104 cells in 100 uL of day 1 endoderm
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media were seeded onto a 20 mL transfection volume of Optimem I Reduced Serum
Media (Invitrogen) containing 0.2 mL RNAiMax per well (Invitrogen) and 10 nM of
either a non-specific scramble siRNA (Applied Biosystems, Foster City, CA) or a siRNA
designed to target the RFP mRNA (IDT, Coralville, IA). Day 1 total well volume was
thus 120 uL. Control samples were seeded into Optimem Media. RNAiMax was utilized
due to its high efficiency of delivering siRNA into hESCs [32]. Differentiation was
performed as previously described, in which 200 uL medium at Day 4 was subsequently
added to each well.

2.6

Colony forming assays
EBs were dissociated as described in flow cytometry. 20,000 cells were diluted

600 uL IMDM supplemented with the following cytokines: 10 U/mL EPO (Amgen), 5
ng/mL GM-SCF (R&D Systems), 10 ng/mL IL-3, and 5 ng/mL GM-CSF (R&D
Systems). The cell/cytokine cocktail was transferred to 4 mL thawed methylcellulose
medium (MethoCult; StemCell Technologies) and vortexed. 1 mL was transferred to
each of 3 35-mm Petri dishes and incubated at 37ºC and 5% CO2 for 12 days.

2.7

Hematologic stains
Selected colonies from methylcellulose culture or cells harvested from suspension

differentiation cultures were washed in PBS and spun onto glass slides with a cytospin
apparatus (Eppendorf) at 800 rpm for 3 min. Slides were stained for 3 min in May15

Grunwald fixation buffer, washed twice in dH2O, and stained with Wright-Giemsa stain
for 18 min.
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3.

Development of a 96-well hESC Differentiation
Assay

3.1

Abstract
Serum-free differentiation protocols of human embryonic stem cells (hESCs)

offer the ability to maximize reproducibility and to develop clinically applicable
therapies. We developed a high throughput, 96-well plate, 4-color flow cytometry-based
assay to optimize differentiation media cocktails and to screen a variety of conditions.
We were able to differentiate hESCs to all three primary germ layers, screen for the effect
of a range of activin A, BMP4, and VEGF concentrations upon endoderm and mesoderm
differentiation, and perform RNA-interference (RNAi)-mediated knockdown of a
reporter gene during differentiation.

Cells were seeded in suspension culture and

embryoid bodies were induced to differentiate to the 3 primary germ layers for 6 days.
Endoderm

(CXCR4+),

mesoderm

(KDR+),

and

ectoderm

(SSEA-3+/NCAM+)

differentiation yields were 75 ± 3%, 96 ± 2%, and 62 ± 3%, respectively. Germ layer
identities were confirmed by quantitative PCR. Activin A, BMP4, and bFGF drove
differentiation, with increasing concentrations of activin A inducing higher endoderm
yields and increasing BMP4 inducing higher mesoderm yields. VEGF drove lateral
mesoderm differentiation. RNAi-mediated knockdown of constitutively expressed red
fluorescent protein did not affect endoderm differentiation. This assay facilitates the
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development of serum-free protocols for hESC differentiation to any target lineage and
creates a platform for screening small molecules or RNAi during ESC differentiation.

3.2

Introduction
Human embryonic stem cells (hESCs) offer the potential to regenerate any cell in

the human body. Initially, many studies utilized serum-containing media to develop
differentiation protocols for target cell types [3, 16-18].

Serum, however, contains

unknown and variable concentrations of growth factors and proteins. More recently,
serum-free differentiation (SFD) protocols have emerged in order to maximize
reproducibility and to gain a more thorough understanding of biological pathways
activated during differentiation to specified lineages [19-21, 33].

Numerous

combinations of cytokines, growth factors, and siRNA molecules are being evaluated in
order to understand signaling pathways utilized during differentiation and to optimize
differentiation protocols to target cell types. By precisely activating or inhibiting the
TGFb family, FGF, Wnt, and other pathways at specific times, the developing embryo
directs differentiation to all somatic cells of the body [5]. In vitro hESC differentiation
systems attempt to recapitulate these developmental pathways by utilizing controlled
concentrations of cytokines and inhibitors. As differentiation proceeds down specific
lineages, the possible number of cytokine combinations dramatically increases. A high
throughput screening method that streamlines the analysis of various growth factor
combinations and their effect upon differentiation would be extremely beneficial.
Only a few groups have developed small scale ESC differentiation systems in
order to probe biological pathways and optimize differentiation media cocktails. Ng et
18

al. [22, 23] have developed a 96-well spin embryoid body (EB) technique in which
hESCs are spun down to form a single EB of a defined size within each well. This
technique has been utilized to optimize differentiation to various stages in the
hematopoietic lineage [24, 25]. Koike et al. have developed a 96-well murine ESC
(mESC) differentiation system and explored effects of EB seeding density upon
differentiation to cardiomyocytes [26, 27]. Due to the small seeding density utilized by
both methods to generate single EBs and the tendency for cell counts to drop over the
first five days of differentiation [24], it is unclear if enough cells would be available for
96-well flow cytometry analyses without pooling wells. Several studies have utilized an
adherent 384-well plate format to screen for small molecule inhibitors or enhancers of
ESC differentiation [28, 29]. Although these confocal microscopy-based assays have
been utilized to screen several thousand small molecules, they are not conducive to multicolor flow-cytometry or live cell sorting.
RNA interference (RNAi)-mediated gene knockdown has also become a common
technique to explore gene involvement in active pathways.

siRNA knockdown of

reporter genes does not affect pluripotency in hESCs grown on mouse embryonic
fibroblasts (MEFs) [34]. Knockdown of OCT4 and NANOG have been shown to induce
differentiation and loss of pluripotency in hESCs [35-37]. RNAi has been utilized to
elucidate signaling pathways that mediate ESC differentiation to multiple lineages [38].
Despite the potential that RNAi offers for understanding biology and modifying pathway
activation, there is little data available regarding any potential off-target effects this
technique may have upon targeted hESC differentiation.
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We have developed a small scale, flow cytometry-based, high throughput hESC
EB differentiation assay. In this study, we differentiate hESCs to the three primary germ
layers and demonstrate biomarker profiles unique to each cell type. We obtained high
cell yields for each layer with remarkably low well-to-well variability.

We also

demonstrate the ability to perform small interfering RNA (siRNA)-mediated gene
knockdown at this scale without disrupting induced differentiation.

These results

demonstrate the utility and efficacy of this system for efficiently optimizing SFD
conditions and performing siRNA knockdown upon numerous targets.

3.3

Results

3.3.1 EB differentiation in 96-well format
We optimized a 96-well plate, 4-color flow cytometry assay for analyzing surface
markers during hESC EB differentiation into target lineages.

A stepwise EB

differentiation protocol was modified to differentiate the cells for 6 days (Fig. 3.1A) [39].
A 4-color biomarker-based flow cytometry assay to detect cells representative of all three
primary germ layers and undifferentiated hESCs in a single sample was developed (Fig.
3.1B). Combinations of the surface markers CXCR4, KDR, NCAM, and SSEA-3 were
assessed to differentiate each cell type.

CXCR4 is a reliable marker for definitive

endoderm [40], but is also expressed in migrating mesoderm [41]. KDR has frequently
been utilized to characterize early mesoderm prior to diverging to a KDR+ lateral lineage
or a PDGFRa+ paraxial lineage [42, 43] and is also expressed at low levels by hESCs
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[39]. SSEA-3 is a marker of pluripotency expressed by hESCs. Upon differentiation,
SSEA-3 expression is lost [44, 45], although expression is maintained at the early
neuroectoderm, neural stem cell stage [46]. NCAM (or CD56) is a neural marker whose
expression is induced during this early ectoderm stage [46] and is a general marker for
ectoderm differentiation [47]. However, NCAM expression is not unique to ectoderm but
is expressed by some endoderm and mesoderm cells as well [48, 49]. Therefore, we
utilized SSEA-3+NCAM- expression to characterize hESCs, CXCR4+KDR- expression
for endoderm, SSEA-3+NCAM+ expression for ectoderm, and KDR+SSEA-3- expression
for mesoderm.

21

Figure 3.1. Experiment schematic and differentiation model. (A) 6-day stepwise
hESC EB differentiation schematic. Differentiation protocols were established in
which cells were fed at days 0, 1, and 4. Cells were seeded into 96-well plates at
day 1 and analyzed by 96-well flow cytometry at day 6. (B) Differentiation and
biomarker expression model. A four-biomarker combination was designed in which
hESCs and cells representing the three primary germ layers could be analyzed in a
single sample.
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A

Figure 3.2. Biomarker time-course analysis. Germ layer differentiation was
initiated at day 0. SSEA-3, NCAM, CXCR4, and KDR surface marker expression
was assessed with flow cytometry at days 0, 2, 4, and 6.
(A) Endoderm
differentiation flow cytometry profiles.
Colored quadrants represent
undifferentiated cells (brown) and differentiation to endoderm (blue), ectoderm
(yellow), and mesoderm (red). Similar mesoderm and ectoderm plots are given in
Figure S1. (B) Marker expression profiles for all differentiation conditions over 6
days of differentiation
In order to examine inter-well variability and percent differentiation, one 96-well
plate was partitioned into 3 induction media zones: endoderm, mesoderm, and ectoderm.
We utilized high activin A with bFGF to induce endoderm [16], high BMP4 with bFGF
to induce mesoderm [39], and simultaneous activin inhibition (SB431542) and BMP4
inhibition (BMP receptor 1A; BMPR1A) with bFGF to induce ectoderm [50, 51] (Fig.
3.1B). The EBs appeared robust and morphologically similar to those grown in bacterial
grade dishes and 6-well plates. 96-well flow cytometry was performed and the different
populations of cells were defined from expression of the four biomarkers (Fig. 3.2A-B,
Fig. 3.3). HES2 endoderm (CXCR4+KDR-), mesoderm (KDR+SSEA-3-), and ectoderm
(SSEA-3+NCAM+) differentiation yields were 74 ± 9%, 74 ± 17%, and 57 ± 8%,
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Figure 3.3. Mesoderm and ectoderm differentiation time course biomarker
expression. Cells were harvested at days 0, 2, 4, and 6 from (A) mesoderm (high
BMP4) and (B) ectoderm (SB431542, BMPR1A) differentiation cultures and
assessed for SSEA-3, NCAM, CXCR4, and KDR expression. Colored quadrants
represent undifferentiated cells (brown) and differentiation to endoderm (blue),
ectoderm (yellow), and mesoderm (red). Abbreviations: SSEA-3, stage-specific
embryonic antigen-3; CXCR, CXC chemokine receptor; KDR, kinase insert domain
receptor; PDGFRa, platelet-derived growth factor-a; BMP, bone morphogenetic
protein.
respectively (Fig. 3.4E). H9 cells demonstrated similar yields of 80 ± 11%, 78 ± 7%, and
41 ± 9% for endoderm, mesoderm, and ectoderm, respectively (Fig. 3.4F). Inter-well
variability was remarkably low between identical induction conditions (Fig. 3.4A-D),
with standard deviations consistently less than 4%.

Activin-/BMP-inhibited media
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retained expression characteristics of pluripotent hESCs (28 ± 17% SSEA-3+NCAM-),
although NANOG and OCT4 transcript expression indicated this is likely due to retained
expression of SSEA-3 in non-NCAM expressing ectoderm (Fig. 3.7A).

25

Figure 3.4. Day 6 phenotypes after differentiation to the three germ layers. (A-D)
Inter-well variability for 96-well flow cytometry expression profiles. hESCs were
seeded into a 96-well plate and differentiated to endoderm, mesoderm, or ectoderm.
Cells were stained for SSEA-3, CXCR4, NCAM, and KDR after 6 days to assess
inter-well variability and the ability to distinguish the separate germ layers. Plots
show percentages of cells expressing the designated surface marker. (E-F)
Biomarker profiles for HES2 and H9 differentiation. Each of the 4 cell types
(hESCs, endoderm, mesoderm, ectoderm) was characterized by a unique biomarker
expression profile. The 96-well format demonstrated highly efficient differentiation
to all three lineages. Error bars represent well means of (E) 2 independent
experiments (n = 2) ± SD and (F) 3 independent experiments (n = 3) ± SD. Each
germ layer was significantly different for its appropriate biomarker at the p < 0.01
level (student’s t-test).
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Cells displayed some toxicity after being seeded at day 0 and then demonstrated
proliferation after 2 days of differentiation (Fig. 3.5). Both endoderm and mesoderm
conditions yielded 4 to 6 day cell counts similar to the initial seeding density of 2x104
cells/well, indicating a potential population plateau for these media. Ectoderm cell yields
(day 6 cell counts compared to day 0 seeding densities) were greater than 300% at day 6,
possibly attributable to the addition of 20 ng/mL bFGF at day 4. In order to evaluate the

Figure 3.5. Differentiation culture cell yield analysis. H9 hESCs were seeded into
96-well plates at day 0 at 20,000 cells/well and differentiated utilizing one of the
three differentiation media: High Activin (endoderm), high BMP4 (mesoderm), and
SB431542, BMPR1A (ectoderm). Cell viability was assessed at days 2, 4, and 6.
Error bars represent the mean ± SD of two independent experiments, each obtained
from the mean of 6 wells on a single plate assay.
effect of seeding density upon differentiation efficiency, we evaluated day 6 marker
expression levels for seeding densities of 8x103 to 6x104 cells/well (Fig. 3.6). The assay
proved to be highly robust for differences in cell densities. Undifferentiated populations
increased with increasing densities, as to be expected due to nutrient and cytokine
depletion.

Mesoderm and ectoderm differentiation efficiency showed a gradual
27

decreasing trend with increasing seeding density, whereas endoderm efficiency was
essentially constant.

Figure 3.6. hESC seeding density analysis. H9 hESCs were seeded at the specified
density into 96-well plates and differentiated to endoderm (high Activin), mesoderm
(high BMP4), or ectoderm (SB431542, BMPR1A). Expression of SSEA-3,
CXCR4, NCAM, and KDR was analyzed with 96-well plate flow cytometry at day
6. Error bars represent the mean ± SD of 3 wells from a single plate assay.
The differentiated populations of cells representative of each primary germ layer,
as well as undifferentiated hESCs, display a unique biomarker profile (Fig. 3.4E-F).
Each cell type was distinguished by increased expression of a combination of biomarkers.
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These findings suggest that this 4-biomarker assay can be utilized to distinguish four
unique cell types after 6 days of differentiation. Furthermore, the three differentiated cell
types have a biomarker profile characteristic of either endodermal, mesodermal, or early
ectodermal cells.

3.3.2 Gene expression verification of induced germ layers
In order to verify that the surface marker profiles obtained using flow cytometry
corresponded to the anticipated lineages, real-time quantitative PCR (qPCR) was
performed on RNA harvested from day 0 hESCs and from cells after 6 days of
differentiation in the various differentiation conditions. The pluripotency genes NANOG
and OCT4 were expressed in undifferentiated cells and as expected were downregulated
in the three conditions inducing cellular differentiation (Fig. 3.7A).

The anterior

primitive streak gene FOXA2 was drastically upregulated in the high activin endoderm
induction conditions, as were the anterior definitive endoderm genes SOX17 and CER1
(Fig. 3.7B). Figure 3.7C displays characteristic gene expression profiles representative of
cells within the posterior primitive streak and differentiating toward mesoderm. These
genes were upregulated in conditions using high BMP4, and are representative of early
stage as well as paraxial (PDGFRa) and lateral progenitor mesoderm (GATA2). Dual
BMP4 and activin A inhibition increased both PAX6 and SOX1 transcript expression
(Fig. 3.7D). The neuronal marker NESTIN was not upregulated in the ectoderm induction
conditions, indicating that these cells have not yet begun to undergo neuralization [52].
These gene expression data support the flow cytometry profiles showing that the three
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defined induction conditions differentiate the cells into lineages representative of
endodermal, mesodermal, and early ectodermal germ layers.

A

B

C

D

Figure 3.7. Germ layer gene expression analysis. Germ layer differentiation was
initiated at day 0. (A-D) RNA was prepared from cells harvested at day 0 (hESCs)
or day 6 and analyzed for genes characteristic of pluripotency (A), endoderm (B),
mesoderm (C), or ectoderm (D) by qPCR. Expression was normalized to the
housekeeping gene GAPDH and all values are relative to hESC expression at day 0.
Error bars represent mean ± SD of 3 pooled wells from a single plate assay.
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3.3.3 96-well growth factor screening assay
We next sought to apply the 96-well flow cytometry assay to efficiently screen
specific growth factors across a range of concentrations. The concentrations of 3 growth
factors, activin A (0-100 ng/mL), BMP4 (0-40 ng/mL), and VEGF (± 10 ng/mL), were
assessed for differentiation to endoderm and mesoderm over the course of 6 days. The
expression of PDGFRa was assessed for an additional mesodermal marker and to
indicate early progression towards the paraxial germ layer [43]. As discussed previously,
SSEA3+, CXCR4+KDR-, and KDR+SSEA-3- expression was used to indicate
undifferentiated cells and commitment of cells to endoderm and mesoderm, respectively.
As expected, expression of the pluripotency marker, SSEA-3, steadily decreased in
conditions with increasing concentrations of activin and BMP4 (Fig. 3.8A).
CXCR4+KDR- expression was nonexistent in the absence of activin A, whereas a low
concentration of activin A (10 ng/mL) was sufficient to induce high (>60% of cells)
CXCR4 expression (Fig. 3.8B). Increasing activin A from 10 to 100 ng/mL increased
CXCR4+KDR- expression for high BMP4 conditions, but otherwise did not have a
notable effect upon CXCR4+KDR- expression. For a constant activin A concentration,
increasing BMP4 consistently reduced CXCR4 expression.

PDGFRa+ and KDR+

populations were greatest in the absence of activin A (Fig. 3.8C-D). Increasing the
activin A concentration immediately abrogated PDGFRa expression. Activin A and
BMP4 displayed a competitive relationship upon KDR+SSEA-3- expression. Increasing
BMP4 concentration increased KDR expression, whereas activin A consistently inhibited
this expression. For most conditions, the additional supplementation of 10 ng/mL VEGF
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had no notable effect upon the expression of this set of cell surface markers (Fig. 3.8AD).

Figure 3.8. 96-well plate growth factor screening analysis. Activin A, BMP4, and
VEGF concentrations were varied over a 96-well plate and SSEA-3+ (A),
CXCR4+KDR- (B), PDGFRa+ (C), and KDR+SSEA-3- (D) expression were
analyzed using flow cytometry after 6 days of differentiation. All samples
contained bFGF (days 1-4: 2.5 ng/mL; days 4-6: 5 ng/mL). VEGF concentration
was ± 10 ng/mL. (A) Pluripotency decreased with increasing activin A and BMP4.
(B) Endoderm populations increased with increasing activin A and decreased with
increasing BMP4. (C-D) Mesoderm character was highest in the absence of activin
A. PDGFRa+ mesoderm was only detectable with no activin. KDR+SSEA-3mesoderm populations consistently increased with increasing BMP4 concentration
and decreasing activin A concentration. All concentrations are ng/mL. Error bars
represent the mean of 2 wells ± SD from a single plate assay.
These data suggest this 96-well flow cytometry assay can be utilized to screen for
the effect of a spectrum of growth factor concentrations upon hESC differentiation in
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serum-free conditions. Furthermore, increased concentrations of both activin A and
BMP4 reduce pluripotency. Increasing activin A concentration increases CXCR4+KDRendoderm populations and reduces both KDR+SSEA-3- and PDGFRa+ mesoderm
populations.

Conversely, increasing BMP4 concentration increases KDR+SSEA-3-

mesoderm populations but decreases CXCR4+KDR- endoderm populations.

3.3.4 Tracking germ layer differentiation through gene expression kinetics
Kinetic analyses can also be performed during the differentiation assays. By
keeping BMP-4 constant at 10 ng/ml, 4 of the previously screened induction conditions
were chosen in which 2 were optimal for endoderm (activin A at 20 ng/ml ± 10 ng/mL
VEGF) and 2 were optimal for mesoderm (activin A at 0 ng/ml ± 10 ng/mL VEGF). All
conditions were carried out on a single 96-well plate. Gene expression profiles were
determined from cells obtained during the six days of differentiation. Genes expressed
during mesoderm and endoderm induction were analyzed, with the inclusion of OCT4 as
a marker of pluripotency in undifferentiated cells.
Mesoderm genes (KDR, PDGFRa, MEOX1, CD34) were consistently expressed
at higher levels in the absence of activin A while endoderm genes (FOXA2, CXCR4,
SOX17) were consistently expressed in the presence of activin A (Fig. 3.9). OCT4
expression steadily decreased in all conditions over the 6 day period.

Brachyury

expression peaked rapidly at days 2-4 and then decreased in all samples, indicative of
ESCs passing through the primitive streak stage [9, 53, 54]. Additionally, non-activin A
conditions demonstrated a clear progression through a Brachyury+KDR- stage to a
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Brachyury+KDR+ stage, indicative of pre-mesoderm to mesoderm/hemangioblast
differentiation [42, 53]. PDGFRa is a marker of mesendoderm [55] and was expressed
in all samples at day 4 followed by increased expression in mesoderm inducing
conditions. CXCR4, while expressed 100 fold higher in the activin A conditions, was still
upregulated 10-fold in the absence of activin A when compared to undifferentiated cells.
This is to be expected since CXCR4 is not entirely endoderm specific but is also

Figure 3.9. Gene expression kinetic analysis. 4 conditions (10 ng/mL BMP4, ± 20
ng/mL activin A, ± 10 ng/mL VEGF) were chosen from the results of the growth
factor screening experiment (Fig. 4) and analyzed for transcript expression levels
during the 6-day differentiation procedure. Pluripotency (OCT4) decreased over
differentiation and Brachyury expression peaked between 2-4 days. Endoderm
genes (FOXA2, CXCR4, SOX17) were expressed much higher for conditions
supplemented with activin A, whereas mesoderm gene expression (KDR, PDGFRa,
MEOX1, CD34) was highest for non-activin A conditions. VEGF increased CD34
and decreased PDGFRa expression at late time-points. Expression was normalized
to the housekeeping gene GAPDH and all values are relative to hESC expression at
day 0. Error bars represent mean ± SD of 3 pooled wells from a single plate assay.
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expressed by migrating mesoderm [41]. This result is consistent with CXCR4 protein
expression detected by flow cytometry (Fig. 3.3A). Generally, the addition of VEGF had
no notable effect upon gene expression, with the exception of lateral (CD34) and paraxial
(PDGFRa) specific genes.

The expression of CD34, a lateral mesoderm and

hematopoietic cell marker, was induced in the absence of activin A but only in the
presence of VEGF. Conversely, the expression of the paraxial gene, PDGFRa, was
highest in the abscence of activin and VEGF, indicating that VEGF drives lateral or
hematopoietic differentiation [43].

3.3.5 siRNA knockdown during endoderm differentiation
In addition to the amount of information that can be derived using this 96-well
format in optimizing growth factor conditions and kinetics, this format is ideal as a high
throughput siRNA screening platform during the differentiation of hESCs. To verify that
siRNA knockdown can be achieved in this 96-well format without disrupting
differentiation, hESCs that constitutively express an RFP protein [30] were utilized.
These cells were induced to differentiate using endoderm conditions and transfected with
a siRNA molecule targeting the RFP mRNA. Following 6 days of differentiation, cells
were analyzed using flow cytometry and qPCR. Both control and mock-treated cells
vividly fluoresced after 6 days, whereas cells exposed to the siRFP molecule only
expressed very low levels of fluorescence (Fig. 3.10A).

To evaluate RFP protein

expression during endoderm induction, both RFP and CXCR4 expression were analyzed
using flow cytometry (Fig. 3.10B). Approximately 85% of both the control cells and
cells transfected with scrambled siRNA were RFP+, compared to 4% of the cells
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transfected with siRNA targeted to RFP. In all conditions, 75-80% of the cells in all
conditions were CXCR4+, with no notable decrease caused by siRFP knockdown. To
further verify that siRNA knockdown had not altered endoderm differentiation, qPCR
analysis was performed after 6 days of differentiation (Fig. 3.10C) to analyze RFP
expression and the anterior primitive streak/definitive endoderm markers FOXA2 and
CER1. RFP transcript expression decreased by 96% as a result of siRNA knockdown.
Neither FOXA2 nor CER1 expression were notably influenced by siRNA knockdown.
These data suggest that siRNA knockdown can be performed in a 96-well format without
significantly altering targeted differentiation.
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Figure 3.10. siRNA-mediated RFP knockdown during endoderm differentiation.
hESCs were reverse transfected with siRFP or a scrambled control when seeded
into 96-well plate format and induced to form endoderm in high activin A SFD
media. (A): Fluorescence microscopy of day 6 EBs. (B) Flow cytometry of day 6
cells showing RFP (y-axis) vs. CXCR4 (x-axis) expression. CXCR4 expression
was not diminished by siRNA-induced RFP knockdown. (C) Gene expression
analysis. qPCR was performed at day 6 to analyze RFP transcript expression as
well as the endoderm genes FOXA2 and CER1. RFP knockdown had no notable
effect upon endoderm differentiation. Error bars represent mean ± SD of 3 pooled
wells from a single plate assay.
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3.4

Discussion
Serum-free and feeder-free hESCs differentiation protocols are essential in order

to 1) maximize experimental control and reproducibility and 2) develop clinically
applicable regenerative therapies [56]. Many studies have focused on titrating growth
factors and inhibitors within SFD cocktails to optimize target cell differentiation. As
lineages are further explored, the possible combinations of factors will inevitably rise.
Screening assays are extremely effective in this pursuit. We have developed a high
throughput, multicolor flow cytometry assay of hESC differentiation that can be utilized
to assess a range of SFD conditions. This small scale format requires approximately 92%
less reagents and growth factors than 6-well culture conditions and occupies 6% of the
incubator space. Additionally, this assay utilizes surface markers to allow for live-cell
analysis and sorting.
We differentiated hESCs to the three primary germ layers in this system,
identified extracellular biomarker profiles for each, and confirmed germ layer identity
with gene expression analysis. A wide variety of extra- and intracellular markers have
been previously utilized to identify each of the primary germ layers.

Given the

heterogeneous expression patterns of endoderm, mesoderm, and ectoderm, no fourmarker combination will perfectly distinguish all cells within each lineage. CXCR4 is
expressed in migrating early endoderm and mesoderm [41], developing vascular
endothelial cells [57], as well as migrating neural stem cells [58]. Although typically 2025% of mesodermal cells expressed CXCR4, our results showed that endoderm was
uniquely distinguishable by CXCR4+KDR- expression at this stage of differentiation.
KDR is expressed on mesoderm cells after exiting the primitive streak [59] and has been
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utilized to characterize hESC differentiation to general mesoderm as well as vascular and
cardiac progenitors [42, 43, 60]. Although our results corresponded with previous studies
that have found KDR expression in a portion of hESCs [39], mesodermal cells generated
by high BMP4 conditions were uniquely identifiable by KDR+SSEA-3- expression.
Currently, no well-characterized extracellular early ectoderm surface markers have been
validated. Ectoderm has typically been characterized by the intracellular markers Nestin,
b-III Tubulin, or Sox1 [51, 61-65]. We exploited the delayed expression of SSEA-3 into
the early neural stem cell stage [46] to overcome the confounding NCAM expression in
endoderm and mesoderm. Transcript expression indicated that this stage is similar to the
primitive anterior neuroectoderm/neuroepithelia stage defined by Pankratz et al. [66],
namely that PAX6 expression is upregulated with SOX1 expression beginning to
increase. This strategy carries the caveat that SSEA-3+NCAM+ phenotyping would not
be applicable at a later stage in the ectoderm lineage due to the loss of SSEA-3
expression.
Although exact comparisons are difficult to make due to various time points,
markers utilized, data reported, and host species differences, we obtained excellent yields
in relation to previous studies.

Serum-containing, high activin A protocols have

produced SOX17+ endoderm yields ranging from 55% [28] to greater than 80% [67] after
5-6 days of differentiation in hESCs. Our yield of 80% for H9 cells falls within the
higher range of this spectrum. Day 6 KDR+ mesoderm populations 15-25% [68] and
52% [69] cells have been obtained from hESCs.

We obtained greater than 74%

KDR+SSEA-3- mesoderm yields for multiple hESC lines. Patani et al. generated day 4
and day 8 yields of 51% and approximately 80%, respectively, for cells positive for the
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neuroectoderm marker MUSASHI from hESCs [70]. Chambers et al. generated greater
than 80% HES5+ neuroectoderm after 11 days of hESC differentiation [50]. Our 6 day
protocol generated yields of 41-57%, comparable to these studies given the shorter time
duration.
Many cytokine conditions, small molecules, and transfection conditions may
induce cellular toxicity. Additionally, seeding densities may be highly variable due to the
inability to seed hESCs as single cell suspensions in many lines. It is vital to obtain
consistent and reliable results from a screening assay despite these caveats. This smallscale culture system demonstrated remarkable inter-well repeatability and densityrobustness, particularly since static EB differentiation systems have been reported to
generate highly heterogeneous cell populations [11]. Since 96- and 384-plate assays can
display variations due to edges, evaporation, thermal variations, and pipetting error [7173], we utilized gas permeable membranes and stainless steel lids to minimize
evaporation and ensure a uniform heat distribution[74]. All standard deviations were less
than 4% for biomarker signals, which allowed for highly significant differences between
conditions.
While many studies have utilized siRNA as a tool for studying ESC
differentiation, there is limited data reporting the presence or absence of off-target siRNA
effects upon differentiation outcome.

Non-viral transfection of off-target siRNA

molecules has been found to induce adipogenesis in human mesenchymal stem cells [75].
Hence, it is important to measure the effects that transfection or transduction may induce
in ESC differentiation protocols.

We found that siRNA-mediated knockdown of

constitutively expressed RFP was highly efficient and induced no notable effects upon
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endoderm differentiation. Cells were transfected with the siRNA molecules at Day 1 of
differentiation and exhibited significant RFP knockdown at Day 6. This assay provides a
siRNA screening platform that can potentially be utilized for differentiation pathway
analysis.
In an effort to demonstrate the efficiency and power of this 96-well assay system,
we conducted a growth factor screening assay utilizing a single 96-well plate and
analyzed 32 conditions in duplicate. We then extended the capabilities of this small-scale
system to analyze time-course gene expression profiles for four of these conditions,
again, within a single 96-well plate. bFGF in combination with activin A or BMP4 drove
differentiation and reduced pluripotency.

In particular, the greatest number of

CXCR4+KDR- cells was induced by low to high activin A with no BMP4. Gene profiles
over the 6 day time period for the activin A + BMP4 conditions confirmed that these
CXCR4+KDR- cells were characteristic of definitive endoderm. These results correspond
to previous studies that found increased CXCR4 expression and increased definitive
endoderm yields by differentiating cells in high activin A containing SFD conditions [67,
76].

Our results are similar to those of Vallier et al. in which high activin A in

combination with bFGF and BMP4 induced mesendoderm [51]. Several studies have
previously reported that activin A + bFGF blocks differentiation and maintains
pluripotency [51, 77], whereas our results demonstrated increased endoderm production.
Our protocol includes a BMP4 exposure step at day 0-1 to serve as a “jumpstart” to
differentiation. The decrease in pluripotent marker expression in subsequent activin A +
bFGF SFD conditions is likely attributable to this step. Activin A and BMP4 exhibited a
competitive effect upon mesoderm marker expression. The presence of activin A alone
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eliminated PDGFRa expression at day 6, although all samples demonstrated transcript
expression through the day 2-4 primitive streak stage. This PDGFRa reducing effect of
activin A has been previously observed [51]. Similarly, activin A reduced KDR+SSEA-3expression, with highest expression levels seen in high BMP4 SFD conditions with no
activin A. These results also corroborate previous studies that have induced mesoderm
and vascular progenitors through BMP4 activation [33, 78] and noted reduced KDR
expression with increasing activin A supplementation [39, 42, 51].
The addition of VEGF to SFD had no notable effect upon surface marker
expression at day 6. However, CD34 transcript expression increased and PDGFRa
expression decreased, indicating a role in inducing early mesoderm cells towards a
hematopoietic lineage.

Indeed, several studies have utilized VEGF to induce

mesendoderm or mesoderm progenitors towards a hematopoietic or cardiovascular state
[24, 39, 79], and VEGF inclusion has been shown to improve subsequent hematopoietic
blast colony formation [42].
Elucidating the optimal serum-free protocols for EB differentiation of hESCs will
require exploring a vast combinatorial field of growth factors, inhibitors, and cytokines.
This small scale culture platform and live-cell flow assay provides a more efficient and
more cost-effective approach to analyzing a large number of conditions.

It can

additionally be utilized to discover biological pathways or optimize differentiation
through RNAi or miRNA screens. By varying biomarkers, this assay can be adopted to
various stages of lineage differentiation to significantly enhance progress towards hESCderived clinical therapies.
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4.

Optimizing Hematopoietic Differentiation

4.1

Abstract
An in vitro method of generating functional hematopoietic cells would alleviate

the strain on the limited availability of donor-supplied cells caused by the widespread
prevalence of hematopoietic malignancies. Embryonic stem cells offer hematopoietic
generating potential, but reported protocols are either not clinically translatable or
inefficient. Additionally, a reliable, defined protocol would allow controversial and
unknown nuances of human embryonic hematopoiesis to be resolved. We have applied a
high throughput hESC differentiation assay to both study hematopoietic differentiation
and optimize the generation of primitive hematopoietic progenitor cells. Specifically, we
performed numerous cytokine and inhibitor screens to develop a stepwise protocol that
utilizes serum-free differentiation medium supplemented with defined concentrations of
growth factors BMP4, VEGF, bFGF, TPO, and IL-3 and the kinase inhibitors Y-27632
and

Chir-99021

to

generate

CD43+CD41+CD235+

primitive

megakaryocyte-

erythromyeloid progenitors and CD41+CD42+ megakaryocytes after 8 and 11 days of
embryoid body differentiation, respectively. We obtain approximately 1 day 8 progenitor
and 1 day 11 megakaryocyte for every 2 initial hESCs.

This highly efficient

differentiation protocol will allow a greater understand of primitive hematopoietic
differentiation.
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4.2

Introduction

4.2.1 Primitive hematopoiesis
Embryogenesis is characterized by two waves of erythrocyte production. The
initial wave, primitive hematopoiesis, occurs in the extraembryonic yolk sac between
embryonic days 7.25 and 9 (E7.25-9) in the murine embryo [80]. This stage is primarily
characterized by the production of transient, large, nucleated “primitive” erythrocytes that
express embryonic globin (e-globin) but not adult globin (b-globin). The second wave,
definitive hematopoiesis, begins around E9.5 within the embryo proper, continues
throughout post-natal life, and is characterized by the production of enucleated, adult
globin-expressing erythrocytes, as well as all adult hematopoietic cells [81].
Primitive hematopoiesis remains an incompletely understood phenomenon,
particularly in humans in which in vivo are essentially not possible. The hallmark of this
process is the production of a hemangioblast, a progenitor cell with both erythrocytic and
endothelial potential. The hemangioblast first originates in the most posterior region of
the primitive streak prior to migrating to the extraembryonic yolk sac [82]. Studies have
also demonstrated myeloid [80] and megakaryocyte [83] potential from early yolk-sac
derived cells, indicating that hemangioblasts can differentiate to these lineages as well.
Although the exact transition from primitive to definitive hematopoiesis is debated,
primitive erythrocytes have disappeared by E9, around the time of definitive onset.
Multipotent progenitors have been found in the yolk sac at E8.5 [84], and hematopoietic
stem cells (HSCs) with long term engraftment potential have been found in the embryo
proper by E10.5 [85].
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Due to ethical and practical difficulties, far less is understood regarding
hematopoiesis in the human embryo. Much of the knowledge of the hemangioblast and
primitive hematopoiesis has now come from ESC studies. Kennedy et al. found that a
progenitor cell with erythrocytic, macrophage, and endothelial differentiation potential
arose within a KDR+ population after 7 days of differentiation [19]. Klimchenko et al.
proved the emergence of a primitive megakaryocyte-erythroid progenitor arising after 9
days of differentiation that could generate primitive erythrocytes and a primitive form of
megakaryocyte whose ploidy remained typically less than 8N [86].
Inducing definitive hematopoiesis in ESC studies has proven much more elusive.
An unknown mechanism must occur to “mature” hematopoietic progenitor cells from
primitive to definitive. This mechanism has so far been provided either by feeder cells or
by serum supplementation. Co-culture of mESCs upon an OP9 murine stromal layer,
characterized by its inability to produce macrophage colony-stimulating factor (M-CSF),
induces differentiation of all hematopoietic lineages [87]. Co-culture upon OP9 cells
along with forced expression of definitive gene HoxB4 induces a definitive HSC capable
of long-term engraftment in adult mice [17, 20]. Undirected EB differentiation in serumcontaining medium induces two sequential waves of primitive followed by definitive
hematopoiesis [18].

Exact pathways involved in these systems have yet to be

determined.

4.2.2 In vitro hematopoietic hESC systems
Due to the paucity of available HSCs for clinical therapies, there is a large need
for in vitro protocols that can reliably produce functional HSCs capable of engraftment in
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humans. In vitro systems also offer the ability to study developmental mechanisms in a
controllable environment. Vodyanik et al. developed an OP9 bone marrow stromal line
coculture system and studied the progression of hESC hematopoietic differentiation [88].
They generated CD34+ primitive hematopoietic cells after 8-9 days of differentiation
capable of generating primitive erythroid, megakaryocytic, and myeloid colonies.
Additionally, after further coculture on MS-5 stromal cells, these cells produced myeloid
and select lymphoid cells.

After further study, it was determined that the CD43+

subpopulation of CD34+ cells generated with this system differentiated committed
hematopoietic progenitors from endothelial and mesenchymal cells [89]. While these
systems shed light on hematopoietic differentiation of hESCs, coculture with animal cells
prohibits translating protocols to the clinic. Furthermore, due to the unknown factors
produced by feeder layers, a thorough understanding of requisite signaling cues was not
possible.
The feeder-free methylcellulose EB differentiation system developed by Zambidis
et al. demonstrated a wave or primitive hematopoietic progenitors characterized by
CD34+CD31+ expression and a second definitive wave from CD45+ cells [18]. While
shedding light on hematopoiesis of hESCs, the use of serum in this system still presented
a need for serum-free systems to be created.
Several studies have developed serum-free hESC hematopoietic differentiation
systems, although hematopoietic progenitor yields have been modest. Pick et al. assessed
combinations of cytokines to optimize hematopoietic differentiation and obtained a 16%
yield after 10 days of differentiation [24]. Chicha et al. utilized an EB based system to
produce CD34+ cells after 8 days capable primitive erythroid and myeloid colony
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forming ability. Up to 20% of total day 8 cells expressed CD34, although no reference to
initial seeding density was made [90]. Niwa et al. utilized a stepwise procedure to induce
KDR+CD34+ progenitors, representing less than 10% of total cell population after 6 days
of differentiation [91].
For clinical translation, protocols will need to generate large quantities of target
hematopoietic cells. This represents a need for high yielding differentiation protocols.
The lack of an efficient serum-free EB protocol to generate hematopoietic progenitors
motivated us to apply the EB differentiation screen to optimize hematopoietic
differentiation of hESCs. Furthermore, we sought to establish a stepwise protocol to
generate megakaryocytes in suspension culture.

4.3

Results

4.3.1 VEGF hematopoietic differentiation screen
Having established conditions to optimize the differentiation of KDR+ mesoderm
cells [92], we initially aimed to investigate inducing cells further down the hematopoietic
lineage. Although VEGF had no effect upon KDR+ expression in our system, it did
induce higher CD34 transcript expression and has been demonstrated to be requisite for
hematopoietic differentiation of ESCs [42]. While previous results had demonstrated the
ability of BMP4 to effectively induce KDR+ mesoderm, we also sought to explore its
relationship upon inducing hematopoietic cells.

Therefore, we performed an EB

differentiation screen by supplementing with 0-40 ng/mL BMP4 and 0-100 ng/mL
VEGF. bFGF was supplemented at 5 ng/mL from days 3-6 (Fig. 4.1A). As opposed to
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prior experiments, BMP4 was removed at day 3 to avoid the differentiation towards
trophoblast and extraembryonic endoderm caused by long term exposure [69]. The panhematopoietic marker CD34 and the hemato-endothelial marker CD31 are the first
hematopoietic markers expressed during OP co-culture of hESCs [88] and were thus
assessed by flow cytometry after 6 days of differentiation.
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Figure 4.1. VEGF and BMP4 hematopoiesis screen. (A) Schematic of the 6-day
differentiation screen with growth factor concentrations. Medium was replaced after 3
days of differentiation. (B) Representative flow cytometry plot of conditions inducing
CD34+CD31+ cells. (C) Percentage of CD34+CD31+ cells for the assayed BMP4 and
VEGF conditions. Results are given as percentages of total cells within each
condition. (D) Cell viability for the assayed conditions. Bars represent the mean ± SD
of two wells.
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Both markers were expressed at approximately the same rates in cells, as
demonstrated by the double positive population in Figure 4.1B. Hematopoietic character
was proportional to the concentration of VEGF in the differentiation medium (Fig. 4.1C).
Conditions lacking VEGF induced roughly 10% of cells toward the hematopoietic
lineage. Increasing concentrations steadily induced higher percentages of total day 6
CD34+CD31+ cells, with approximately 40% of cells in 100 ng/mL VEGF medium
expressing both markers. There was no clear relationship between BMP concentration
and early hematopoietic character.
In contrast to general mesoderm conditions from previous experiments,
hematopoietic differentiation conditions were characterized by low and highly variable
viability (Fig. 4.1C). Viability generally increased with increasing concentrations of
VEGF.

BMP4, conversely, induced lower cell counts, although trends were not

consistent.

These data suggest that the 96-well assay could be utilized to screen

hematopoietic differentiation conditions.

Additionally, VEGF supplementation

concentration is proportional to the percentage of cells characteristic of early
hematopoietic cells and induces higher viability after 6 days of differentiation.
Increasing BMP4 concentrations tends to result in lower viability.

4.3.2 Hematopoietic differentiation in 96-well format
Having established the capability and basic conditions for early hematopoietic
differentiation in 96-well format, we next sought to explore cell phenotype over a longer
period of differentiation. Cells were seeded into 96-well plates at day 0 with 25 ng/mL
BMP4 and 50 ng/mL VEGF, and medium supplemented with 5 ng/mL bFGF was added
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at days 2 and 6 (Fig. 4.2A-B). In an effort to increase viability following differentiation,
the Rho-associated protein kinase (ROCK) inhibitor Y-27632 was added to differentation
medium for the first 48 hours [93]. EBs were dissociated and various hematopoietic
markers were assayed by flow cytometry at days 4 and 8.
After 4 days of differentiation, EBs ranged in size from 50-300 mM in diameter
(Fig. 4.2D). A distinct KDR+CD31+CD34+ population of cells had emerged (Fig 4.2C).
These cells were absent of CD43 and CD41 expression. Most cells were KDR+ and 33%
± 3% had begun expressing CD34.

As observed previously, CD34+ cells typically

expressed CD31 as well. Few cells had begun to express the pan-hematopoietic marker
CD43 or the erythrocytic marker CD235a. Essentially all CD31+ cells were also KDR+
(Fig. 4.2C). CD31 expression was preceded by KDR+ expression by about 24 hours (data
not shown).
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Figure 4.2. 96-well hematopoietic differentiation setup and day 4. (A) Schematic
of 8 day hematopoietic differentiation. (B) Cells at Day 0 after seeding in
suspension into 96-well format. Scalebar, 1000 mM. (C) Day 4 flow cytometry
profiles demonstrating the KDR+CD31+CD34+ population. (D) Day 4 EBs. (E)
Day 4 hematopoietic marker profiles. Bars represent mean ± SD of 3 wells.
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Figure 4.3. Day 8 hematopoietic cells. (A) Day 8 EBs. (B) Day 8 hematopoietic
marker profiles. Bars represent mean ± SD of 3 wells. (C) Day 8 flow cytometry
profiles. Cells within the gated CD31+CD43+ population in the upper left plot are
highlighted in green in remaining plots.
After 8 days of differentiation, EBs had adopted a much larger cystic, vacuolated
morphology with some EBs measuring 400 mM in diameter (Fig.4.3A).
appeared to be emitting single cells in suspension.

EBs also

While the KDR+CD31+CD34+

population was still present, a small CD43+CD31+KDRlow/- population had emerged (Fig.
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4.3C). These cells also expressed CD235a and the megakaryocytic marker CD41 and
were CD34+/-. This population only represented approximately 3% of total cells.
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Figure 4.4. Day 8 separated EBs and single cells. (A) Day 8 flow cytometry
profiles. (B) CD31, CD43 expression for EB cells. (C) Flow cytometry plots for
single cells demonstrating CD43, CD41, and CD235a expression. (D) Cell viability
over 8 days of differentiation.
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It was hypothesized that this CD43+ population consisted of single cells released
from EBs. In order to evaluate this possibility, wells were pooled and EBs were allowed
to settle for several minutes. The supernatant was then withdrawn, EBs were dissociated,
and flow cytometry was performed on both sets of cells. EBs exhibited almost no
expression of the hematopoietic markers CD43, CD41, and CD235a, whereas more than
90% of single cells expressed CD43 (Fig. 4.4A-C). Approximately 20% of single cells
had also begun expressing the committed megakaryocytic marker CD42a.
Cell viability immediately decreased following seeding at Day 0.

Day 4

populations were still less than 40% of the initial number of hESCs seeded (Fig. 4.4D).
Yield had grown to higher than 50% at day 8, although the magnitude of single cells was
lower than 500 cells/well, representing less than a 2.5% yield.
This data suggests that as hematopoietic differentiation proceeds, an early
population of KDR+CD31+CD34+ cells is generated by day 4 and gives rise to a
CD31+CD43+CD41+CD235a+ population by day 8.

This day 8 population emerges

predominantly as single cells released by EBs. Although not shown, a very small amount
of these cells (several cells per well) was observed at day 6.
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Figure 4.5. Schematic of 6-well scaled up procedure and single cell progenitor
assays. Single cells were isolated at day 7 of differentiation and either cultured in
methylcellulose for CFC analysis or re-suspended in differentiation medium
supplemented with various cytokines to monitor differentiation progression.
In order to characterize the hematopoietic potential of the day 7-8 single cells and
verify the scalability of this system, hESCs were differentiated in identical conditions in
6-well culture format. Single cells were isolated after 7 days of differentiation and
seeded into methycellulose and supplemented with hematopoietic cytokines to test colony
forming potential (Fig. 4.5). At day 7, heterogenous EBs and single cells were both
visible in cultures (Fig. 4.6A). Over 90% of single cells were CD43+CD31+ (Fig. 4.6B).
41% were CD41+CD235a+, with some cells already expressing single lineage markers.
Cells were KDRlow/- and approximately 70% were CD34-. Approximately 10% of cells
expressed a CD41-CD34+ phenotype.
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Figure 4.6. Phenotype of day 7 cells. (A) Day 7 EBs and single cells. Scalebar,
400 mM. (B) Flow cytometric marker profiles of day 7 single cells.

After 12 days of methylcellulose culture, cells had given rise to colonies of
primitive erythrocytic, macrophage, and mixed morphology (Fig. 4.7A, B). Cytospins
and May-Grunwald-Giemsa staining were then performed on selected colonies and
demonstrated primarily primitive erythroblast and macrophage cells.

These results

suggest that differentiation conditions identified by the 96-well assay are scalable to 6well plate or larger formats and that single cells produced after 7 days of differentiation
have erythromyeloid potential.
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Figure 4.7. Hematopoietic colony potential of isolated day 7 single cells. (A)
Colonies observed after 12 days of methycellulose culture and corresponding
cytospins demonstrating primitive erythroblasts and macrophages. EP: primitive
erythrocyte colony; Mac: macrophage colony (B) Colony frequencies after 12 days.
Bars represent mean ± SD of three assays.
Differentiating day 7 suspension single cells for a further 4 days in hematopoietic
medium (containing SCF, TPO, EPO, Flt3-L, IL-6, and IL-3) produced cells
morphologically characteristic of blast cells, primitive erythrocytes, and myeloid cells
(Fig. 4.8A).

At least three distinct populations were evident based off of marker

expression profiles (Fig. 4.8B).

A CD41highCD42a+CD235a-CD43high population

indicated the presence of committed megakaryocytes (approximately 25% of cells). A
CD235a+CD41-CD43mid/low population indicated committed erythrocytes.

A separate

CD41low/-CD235a-CD43high/midCD31high/midKDRmid population also existed, although it
was not clear what these represented. Almost all cells were CD34- and slight CD18 and
CD45 expression indicated progression towards myeloid lineages. This suggests that day
7 single cells are capable of further differentiating down the erythroid, megakaryocytic,
and myeloid lineages.
57

Figure 4.8. Hematopoietic differentiation phenotypes of day 7 + 4 cells. (A)
Cytospin of day 7 suspension cells showing blast cell morphology. (B) Flow
cytometry marker profiles.

After 10 days of differentiation of isolated single cells, populations began to
appear less distinct. Committed CD235a+ erythroid and CD41+CD42a+/- megakaryocytic
populations were still evident, although both had declined (Fig. 4.9B).

A new

CD43lowCD41-CD235a- population was evident. Myeloid populations, characterized by
CD18 and CD45 expression, had increased.

Cytospins revealed multilineage cells

resembling mature erythrocytes, megakaryocytes, and myeloid cells (Fig. 4.9A). These
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data suggest that multipotent day 7 progenitors do not continue to self-renew and produce
new committed progeny when cultured in the utilized differentiation medium.

Figure 4.9. Hematopoietic differentiation phenotypes of day 7 + 10 cells. (A)
Cytospin of day 7 suspension cells, showing cells characteristic of erythrocytes (E),
megakaryocytes (MK), macrophages (Mac), and neutrophils (NP). (B) Flow
cytometry marker profiles.

4.3.3 Optimizing KDR+CD31+ and CD31+CD43+ differentiation
These experiments indicated that during EB hematopoietic differentiation of
hESCs, cells progress first through a KDR+CD31+ stage before CD43+ primitive
megakaryocyte-erythromyeloid progenitors are produced and that BMP4 followed by
VEGF supplementation was required to induce CD31+ expression. However, yields of
CD43+ single cells remained modest. We next sought to optimize the yield of these
populations by increasing differentiation percentages and viability.
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During mesoderm differentiation, BMP4 activates the Wnt pathway indirectly and
Wnt signaling is required for primitive streak and mesoderm differentiation of mESCs

Figure 4.10. Simplified schematic of Chir-induced b-Catenin nuclear translocation.
Chir inhibits phosphorylation of b-catenin by GSK3, preventing ubiquitination in
inducing nuclear translocation and subsequent mediation of downstream genes.
[42, 94]. However, addition of exogenous Wnt to BMP4-supplemented conditions does
not significantly improve hematopoietic differentiation [42]. Prior to differentiation, Wnt
supplementation induces proliferation in undifferentiated hESCs [95].

The canonical

WNT pathway relies on the nuclear translocation of the transcription factor b-catenin to
the nucleus [96].

In the absence of exogenous WNT signaling, b-catenin is

phosphorylated by the glycogen synthase kinase 3 (GSK3) and subsequently
ubiquitinated and degraded. The small molecule Chir-99021 (herein referred to as Chir)
is a highly selective inhibitor of GSK3b [97]. Inhibition of GSK3 activates the WNT
pathway by preventing the degredation of b-catenin (Fig. 4.10). We hypothesized that
GSK3 inhibition during concomitant BMP4 supplementation may enhance yields by
inducing proliferation during differentiation. Our first objective was to evaluate the
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effect of GSK3 inhibition, and consequently WNT activation, upon EB-based
hematopoietic differentiation of hESCs.
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A

B

Figure 4.11. KDR-CD31 profiles for Chir, BMP4, VEGF Screen. (A) Day 6 and 8
profiles for all conditions. The double positive population is clear at day 6 and the
CD31+KDRlow/- population is evident at day 8. (B) Time-course flow plots over 8 days
of differentiation for medium supplemented with 2 mM Chir and 0 ng/mL BMP4.
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We performed a screen to evaluate the effects of Chir supplementation upon a
range of BMP4 and VEGF concentrations. hESCs were seeded at day 0 with ± Chir in
conditions supplemented with 0-40 ng/mL BMP4 and 0-100 ng/mL VEGF. Chir was
removed after 48 hours by replacement with bFGF-containing medium. After 6 days of
differentiation, the KDR+CD31+ early hematopoietic population was observed in all
VEGF and BMP4 containing conditions, as expected, and additionally in the Chirsupplemented conditions with 0 ng/mL BMP4 (Fig. 4.11A). CD31+KDRlow/- cells were
evident in all VEGF and BMP4-containing conditions at day 8 and in Chir-exposed
conditions without BMP4. Additionally, in Chir-conditions, this population surprisingly
declined with increasing BMP4 concentrations. Smaller populations of these cells were
also observed in wells containing both Chir and BMP4. Time course flow cytometry
demonstrated that CD31+ expression was delayed by up to 2 days by replacing BMP4
with Chir (Fig. 4.11B).

Chir also greatly enhanced post-seeding cell viability,

particularly in the absence of BMP4 (data not shown). This observation indicated that
Chir supplementation may compliment or replace BMP4 supplementation and may
enhance viability. Smaller CD31+KDRlow/- for increasing BMP4 concentrations in Chirexposed conditions indicated that higher concentrations of BMP4 may inhibit
hematopoietic differentiation.
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Figure 4.12. Day 3 results of the hematopoietic screen with Chir. (A) Experiment
schematic (B) Images of EBs for the three conditions, all with 2.5 ng/mL BMP4.
Scalebar, 1000 mM. (C) KDR, SSEA3 flow cytometry profiles of conditions. (D)
Flow cytometry marker expression profiles. Expression values are given as percent
of total live cells. Bars represent the mean ± SD of 4 wells. B-D0-3: BMP4
supplementation from Days 0-3. Chir concentration was 2 mM.
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To evaluate these possibilities, a repeat screen was performed upon BMP4
concentrations of 0-10 ng/mL. Unlike the previous experiment, Chir was replaced with
bFGF containing medium at day 1. BMP4 was supplemented for either days 0-3 or days
1-3 (Fig 4.12A). After 3 days and throughout differentiation, EBs in Chir-containing
conditions were more defined and exhibited less surrounding apoptotic cells (Fig 4.12B).
After 3 days of differentiation, Chir notably induced greater differentiation, as evidenced
by lower SSEA3 expression (Fig 4.12C). Dual BMP4 and Chir supplementation induced
the early mesoderm KDR+ population, whereas this population had yet to emerge in
conditions without Chir. A smaller KDR+ population was evident in conditions without
BMP4 for the first 24 hours.

In Chir-containing conditions, KDR expression was

proportional to the concentration of BMP4, with over 80% of cells KDR+ when
supplemented with Chir and 10 ng/mL BMP4.
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Figure 4.13. Day 5 results of the hematopoietic screen with Chir. (A) Images of
EBs for the three conditions, all with 2.5 ng/mL BMP4. Scalebar, 1000 mM. (B)
CD31, KDR flow cytometry profiles of conditions.
(C) SSEA3+ and
+
+
CD31 KDR marker expression profiles. Expression values are given as percent of
total live cells. Bars represent the mean ± SD of 4 wells. Day 0 cell seeding
density is represented by the red dashed line. Chir concentration was 2 mM. B-D03: BMP4 supplementation from Days 0-3.
After 5 days of differentiation, Chir EBs continued to remain larger than BMP4
alone EBs (Fig. 4.13A). Postponing BMP4 supplementation by 24 hours resulted in
smaller EBs. BMP4-containing conditions displayed similar KDR+CD31+ populations,
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with efficiencies generally ranging 50-65% (Fig. 4.13B, C). This population appeared to
plateau for BMP4 concentrations greater than 2.5 ng/mL. Delaying BMP4 addition in
small concentrations by 24 hours again delayed differentiation, as noted by increased
SSEA-3 expression and decreased CD31 expression. Although Chir induced higher
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Figure 4.14. Day 5 viability. Expression values are given as percent of total live
cells. Bars represent the mean ± SD of 4 wells. Day 0 cell seeding density is
represented by the red dashed line.
KDR+ populations at day 3, there was no corresponding increase in CD31+KDR+ cells at
day 5. Yields, however, were significantly higher for Chir containing conditions due to
higher viability (Fig. 4.14). Samples exposed to Chir without BMP4 for 24 hours were
extremely variable. For BMP4 concentrations greater than 5 ng/mL administered at day
1, Chir supplementation increased cell counts by an average of 5-fold.

However,

viability was similar to BMP4 alone conditions for lower concentrations. Simultaneous
Chir and BMP4 supplementation at day 0 increased viability by approximately 100%
over BMP4 supplementation alone.
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Figure 4.15. Day 8 results of the hematopoietic screen with Chir. (A) Images of
EBs for the three conditions, all with 2.5 ng/mL BMP4. Scalebar, 1000 mM. (B)
CD31, CD43 flow cytometry profiles of conditions. (C) CD31+CD43+marker
expression profiles and cell viability. Expression values are given as percent of
total live cells. Bars represent the mean ± SD of 4 wells. Day 0 cell seeding
density is represented by the red dashed line. Chir concentration was 2 mM. B-D03: BMP4 supplementation from Days 0-3.
As seen previously, CD43+ cells had begun to emerge by day 8, most
predominantly in BMP4-containing conditions EBs were typically more frequent and
larger for Chir conditions (Fig. 4.15A).

For small concentrations of BMP4 (2.5-5
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ng/mL), Chir enhanced CD43+ differentiation, whereas no difference in induction
percentage was seen at 10 ng/mL (Fig. 4.15B-C). Postponing BMP4 supplementation by
24 hours had no significant effect upon CD43+ differentiation percentages.

In all

samples, BMP4 concentration was proportional to the size of this population. Although
large variances were observed, Chir induced higher total cell viabilities than BMP4 alone
(Fig. 4.15C). Cell counts were generally at least double those of BMP4 alone.
The CD43+ populations were still present at day 11, indicating that these cells
either remain viable over this period or are replaced by newly differentiating cells. EBs
were similar to day 8, although larger cystic EBs were more frequent in Chir containing
conditions (Fig. 4.16A). The KDR+CD31+ population was still present and relatively
larger than day 8 for Chir conditions. CD43 relative population sizes were generally
similar to day 8, although the day 0 BMP4 + Chir conditions demonstrated decreases.
Notably, Chir supplementation with no BMP4 induced a population of CD43+ cells
unobserved at day 8 (Fig 4.16B). Similar to day 8, viability remained increased in Chircontaining conditions.
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Figure 4.16. Day 11 results of the hematopoietic screen with Chir. (A) Images of
EBs for the three conditions, all with 2.5 ng/mL BMP4. Scalebar, 1000 mM. (B)
CD31, CD43 flow cytometry profiles of conditions. (C) CD31+CD43+marker
expression profiles and cell viability. Expression values are given as percent of
total live cells. Bars represent the mean ± SD of 4 wells. Day 0 cell seeding
density is represented by the red dashed line. Chir concentration was 2 mM. B-D03: BMP4 supplementation from Days 0-3.
Differentiation percentages and absolute cell counts were utilized to determine
yields of target cells over the course of differentiation (Fig. 4.17). In particular, we
assessed the yields of target hematopoietic cell populations at different timepoints in
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comparison to the initial seeding density of 20,000 cells per well. Early hematopoietic
populations were significantly increased for all BMP4 conditions in the presence of Chir.
At day 3, yields were greater than 80% of cells expressing KDR when BMP4
concentrations greater than 5 ng/mL were supplemented with Chir, compared with less
than 5% of cells in the corresponding conditions without Chir (p<0.01). Subsequently at
day 5, mid-range BMP4 and Chir concentrations demonstrated approximately 75% yields
for KDR+CD31+, compared to less than 40% in the absence of Chir. Similarly at day 8,
CD43+ yields greater than 45% were observed when BMP4 concentration was at least 5
ng/mL in the presence of Chir, compared to less than 25% in its absence. Surprisingly, at
day 11, conditions with Chir and no BMP4 demonstrated a yield of 34 ± 2%.
These results indicate that 24 hour exposure to Chir in the presence of
concentrations of BMP4 less than 10 ng/mL enhances EB hematopoietic differentiation,
resulting in more early-stage hematopoietic cells emerging at earlier time points.
Additionally, Chir supplementation in the absence of BMP4 induces efficient
hematopoietic differentiation, albeit at a delayed scale. Initial Chir supplementation
during hematopoietic differentiation greatly increases cell viability in 96-well format.
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Figure 4.17. Differentiation yields throughout 11 days of differentiation. Yields
are given for conditions supplemented with BMP4 from days 0-3 with and without
2 mM Chir. Percentages are relative to the initial day 0 seeding density of 20,000
cells/well. Asterisks in lower graph represent significant differences when
compared to the corresponding condition without Chir in the top graph (*: p<0.05;
**: p<0.01). B-D0-3: BMP4 supplementation from Days 0-3.
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4.3.4 Cytokine screen to enhance CD43+ progenitor differentiation and
megakaryopoiesis
We established a step-wise procedure to differentiate hESCs down the
hematopoietic lineage to obtain CD43+CD41+CD235+ cells characteristic of common
myeloid progenitors. This procedure demonstrated that the growth factors BMP4, VEGF,
and bFGF were sufficient to induce this cell population. We also found that an initial 24
hour exposure to the GSK3b inhibitor Chir-99021 enhanced viability and hematopoietic
differentiation.

Prior studies have shown that supplementation with various

hematopoietic cytokines further enhances hematopoietic differentiation and is required
for commitment to several specific lineages [86, 98, 99]. However, requirements of these
factors to hemopoietic differentiation of hESCs in serum-free medium have not been
assessed. Many hematopoietic differentiation protocols of ESCs have included cytokines
at various stages without detailing their contribution. Additionally, reports have included
such factors in differentiation medium and noted no apparent benefit in blast colony
formation [100]. We sought to perform a screen of various hematopoietic cytokines to
assess their potential enhancement to production of CD43+ progenitors and CD41+CD42+
megakaryocytes.
hESCs were differentiated according to the previously established stepwise
protocol, including an initial 24 hour exposure to Chir-99012 (Fig. 4.18A). At day 6,
cells were exposed to medium supplemented with 10 ng/mL bFGF, 100 ng/mL VEGF,
and various cytokine combinations: ± 25 ng/mL FLT3-L, ± 10 ng/mL IL-3, ± 10 ng/mL
IL-6, and ± 50 ng/mL TPO. Cell identity and viability were assessed at days 8 and 11.
After 8 days of differentiation, CD31+CD43+ yields were similar amongst all conditions,
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ranging between 40-65%, with no clear trends due to the presence or absence of different
growth factors (Fig. 4.18B). Viability was above the seeding density of 20,000 cells per
well for most conditions (Fig. 4.18C).

Figure 4.18. Experiment schematic and day 8 hematopoietic cells. (A) Schematic
of hematopoietic cytokine screen. (B) CD31+CD43+ populations. Percentages
represent percentage of total cells. (C) Total cell viability. Bars represent mean ±
SD of two wells.
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Figure 4.19. Day 11 CD43+ hematopoietic populations. (A) Marker profiles
demonstrating gated CD43+CD31low/- hematopoietic cells out of total cells (left) and
CD41 and CD235a expression for those gated cells. (B) CD43+ populations.
Percentages represent percentage of total cells. (C) CD43+ percentage yields.
Values are given as percentage of 20,000 cells/well seeded at day 0. Bars represent
mean ± SD of two wells.
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After 11 days of differentiation, cells had begun to differentiate down more
committed lineages. Viability was higher for cells exposed to both TPO and IL-3 (Fig.
4.19A). IL-6 appeared to increase viability in the absence of IL-3. Several general
marker expression trends were evident for all samples. The hematopoietic progenitor
population maintained CD43 but began to express lower CD31 expression than observed
at day 8 (Fig. 4.19B). A subpopulation of CD43+ cells had lost CD41 expression,
indicating commitment to a non-megakaryocytic lineage. Approximately one-third of
these cells expressed CD235a, indicating differentiation toward the erythrocytic lineage.
CD41+CD235a+ cells were still observed, although a population of CD41+ cells had lost
CD235a expression, indicating progression towards the megakaryocytic lineage.
Population sizes began to vary between the various cytokine conditions.

CD43+

differentiation percentages were increased for IL-3-containing conditions (Fig. 4.19C).
When viability was taken into account, CD43+ yields were greater for cells exposed to
both TPO and IL-3 and to cells exposed to both TPO and IL-6 (Fig. 4.19D). This
phenomenon emphasized the need to assess both marker expression percentages and
yields. Differences in the former imply an influence upon differentiation efficiency; in
the latter, upon proliferation.
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Figure 4.20. Day 11 CD41+ hematopoietic populations. (A) Marker profile
demonstrating the CD41+CD31low/- population. (B) Differentiation percentages and
yields for total CD41+. Percentages represent percentage of total cells (left) and
percentages of 20,000 cells/well seeded at day 0 (right). Bars represent mean ± SD
of two wells.

CD41+ cells exhibited the CD31low/- phenotype (Fig. 4.20A).

Differentiation

percentages ranged between 28-40% of total cells, with TPO and IL3 inducing more
efficient differentiation although not significantly (Fig. 4.20B). The greatest cell counts
were obtained for conditions supplemented with only TPO and IL-3, with a yield of
21,900 ± 350 cells/well, or approximately 110% of the initial hESC cell density. When
used in combination with TPO and IL-3, IL-6 and FLT3-L appeared to decrease yield
slightly, but not significantly so. Removing either TPO or IL-3 significantly reduced
CD41+ cell generation.
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Figure 4.21. Day 11 CD42+ megakaryocyte populations. (A) Marker profile
demonstrating the CD41+CD42a+ population. (B) Differentiation percentages and
yields for total CD42a+. Percentages represent percentage of total cells (left) and
percentages of 20,000 cells/well seeded at day 0 (right). Bars represent mean ± SD
of two wells.
A portion of CD41+ cells had begun to express CD42a, indicating commitment to
the megakaryocyte lineage (Fig. 4.21A). These cells generally represented 40-50% of
total CD41+ cells. Due to variability, various cytokine combinations failed to significant
affect CD42+ differentiation efficiency (Fig. 4.21B).

However, as with CD43+ and

CD41+ cells, CD42a+ megakaryocyte yields were higher for TPO and IL-3 containing
conditions, with TPO and IL-3 together generating a yield of 48 ± 4% (Fig. 4.21B).
FLT3-L again appeared to inhibit CD42a+ cell production in the presence of TPO and IL3, although this trend was true for CD43+ hematopoietic cells in general (Fig. 4.19D).
IL-6 appeared to inhibit CD42a expression in the presence of TPO and IL-3.
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These data suggest that supplementing the stepwise differentiation protocol with
hematopoietic cytokines enhances hematopoietic progenitor generation after 11 days of
differentiation by influencing both differentiation efficiency and cell proliferation. More
specifically, TPO and IL-3 increased the proportion of CD43+ cells. These two cytokines
also increased CD43+, CD41+, and CD42a+ yields by inducing greater proliferation
between days 8 and 10. For conditions containing only TPO and IL-3, CD41+ and
CD42a+ cell yields were approximately 100% and 50%, respectively.

4.4

Discussion
Here, we applied the 96-well EB differentiation assay to optimize distinct stages

of hematopoietic differentiation of hESCs. Specifically, we developed a stepwise serumfree protocol to efficiently differentiate hESCs toward CD41+ primitive common myeloid
progenitors and CD42+ megakaryocytes (Fig. 4.22). Combinations of BMP4, VEGF,
bFGF, TPO, and IL-3, along with the ROCK inhibitor Y-27632 and the GSK-3b
inhibitorChir-99021, are utilized at distinct times during an 11 day differentiation in
serum-free medium. Along the procedure, cells transition from pluripotent ESCs to
KDR+ early mesoderm, KDR+CD31+ hematopoietic cells, CD43+CD41+CD235+
progenitor cells, and CD41+CD42+ megakaryocytes.
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Figure 4.22. The final stepwise hematopoietic and megakaryocyte differentiation
protocol.

Initially BMP4 and Chir-99021 are utilized to push the hESCs to the primitive
streak stage. BMP4 has been shown to induce primitive streak differentiation and have a
“posteriorizing effect” upon streak cells, further pushing them toward KDR+ mesoderm
[33, 42]. In our system, BMP4 effectively induced KDR+ mesoderm and KDR+CD31+
mesoderm, but cell death was high, limiting the information content of endpoint flow
cytometry results.

Wnt signalling is required for both primitive streak and KDR+

mesoderm formation [42, 94]. However, Wnt supplementation in addition to BMP4 has
been shown to have little contributory effect toward either streak formation or KDR+
mesoderm [42].

Our results demonstrated that simultaneous Chir and BMP4

supplementation increased viability by approximately two-fold and notably enhanced
differentiation yields of hematopoietic cells throughout differentiation.

Chir

supplementation prior to BMP4 exposure drastically increased cell counts in some
conditions, consistent with the previous observation of Wnt-stimulated hESC
proliferation [95].
The

exact

mechanisms

underlying

hematopoietic differentiation are unclear.

Chir-induced

enhanced

primitive

The requirement of Wnt signaling in the

mesoderm-to-hematopoietic transition is more established.

In murine ESCs, BMP

activates Wnt3a, which in turn promotes hematopoiesis via the Cdx-Hox pathway [101].
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Wnt signaling has also been shown to be required for post-mesoderm primitive but not
definitive hematopoiesis in mESCs [42].

Our results demonstrated enhanced

hematopoietic differentiation following an initial 24-hour activation of the Wnt pathway,
as indicated by the action of Chir. These results conflict with those of a previous study
showing that Wnt treatment prior to primitive streak formation induces a mesoderm to
cardiomyocyte route in mESCs [102].

However, these results were obtained in

undirected, serum-containing medium, obfuscating the underlying mechanisms. Indeed,
human induced pluripotent stem cells (iPSCs) generated KDR+ progenitors with erythromyeloid potential after 8 days of differentiation in WNT3a-containing serum-free
medium [103]. In agreement with our results, co-culture of hESCs on a Wnt1-producing
stromal line, which activates canonical Wnt signaling, enhanced differentiation of
KDR+CD31+CD34+ cells. This was not observed by activation of the non-canonical
pathway [104].
The ROCK inhibitor Y-27632 is known to increase viability during hESC
passaging [105] and has been shown to increase cell survival within the first 24 hours of
differentiation initiation [93]. Due to the low viability observed during hematopoietic
differentiation and the heightened concern due to the small culture format, Y-27632 was
added for initially 48 hours and subsequently 24 hours at day 0 in the stepwise protocol.
Although Y-27632 has been reported to decrease post-thawing viability and expansion of
frozen CD34+ cord blood cells [106], we observed no negative effects upon
hematopoietic differentiation.
Previous studies have documented the requirement of VEGF for hematopoietic
differentiation of ESCs [42, 107, 108], but to our knowledge none had characterized the
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relationship between concentration and differentiation efficiency.

We directly

demonstrated that VEGF is required for generating CD34+CD31+ cells and that its
concentration is proportional to differentiation efficiency. Furthermore, we showed that
these cells are also KDR+. Although we did not characterize the exact identity and
potential of these cells, it is likely that, prior to emergence of the CD43+ cells, this
population contains the KDR+ hemangioblast previously described that exhibits
primitive-erythroid and myeloid potential [19].
CD43 expression marks the commitment of differentiating hESCs to the
hematopoietic lineage [89]. We first detected CD43+ expression within a population of
CD43+CD41+CD235+ single cells that emerged between days 7-8 in this system. We
found these cells to have primitive-erythroid, megakaryocyte, and myeloid potential.
Past studies have defined a CD41+CD235+ bipotent primitive erythroid-megakaryocyte
progenitor (MEP) capable of differentiating towards the primitive erythroid or
megakaryocyte lineages in both murine embryogenesis [83] and hESC OP9 coculture
[86]. However, these studies did not assess myeloid potential. The primitive MEP
generated by OP9 coculture expressed CD34 shortly after emergence, whereas our
progenitor did not. Macrophage potential arises within the murine yolk sac at the same
time as primitive erythroid potential [80], indicating that these lines share a common
progenitor. Thus, it is difficult to state definitively whether the cell we have generated
represents an identical or analogous cell type to previous studies. It is perhaps better
described as a primitive version the common adult myeloid progenitor [109].
In this study, hematopoietic potential was evaluated based off of entire
populations of single cells without sorting. Thus, we can not definitely state which cell
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possesses common myeloid potential. Prior studies have demonstrated that unilineage
CD235+ erythrocytes and CD41+ megakaryocytes arise from CD235+CD41+ bipotential
progenitors [83], and thus it is reasonable to hypothesize the same here. We observed
both CD34+ and CD34- cells within CD41 populations at day 7. It is not clear if either
offers more progenitor capabilities. Zambidis et al. found more colony forming potential
in CD143+CD34- than in CD143+CD34+ early hematopoietic cells [108]. Chicha et al.
reported a differentiation system in which CD34+ cells generated myeloid and mature
erythroid colonies whereas as CD34- cells produced only small immature erythoid
colonies [90]. The relationship between CD34 expression and progenitor potential is
clearly not fully understood.
IL-3 has been previously shown to enhance primitive erythroid colony formation
from hESC derived primitive MEPs and has frequently been used in hematopoietic
differentiation protocols [86, 91]. TPO promotes megakaryopoiesis by binding to its
receptor c-Mpl [99] and is also commonly utilized in protocols [90, 91, 100, 110]. We
found that Chir-99021, BMP4, VEGF, and bFGF supplementation were sufficient to
generate CD43+ committed hematopoietic progenitors and megakaryocytes, but highest
yields were generated when TPO and IL-3 cytokines were added in combination to the
differentiation medium. FLT3L had no apparent effect after 11 days of differentiation.
In the absence of IL3, IL6 increased hematopoietic yields when used in combination with
TPO.
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5.

Conclusions, Limitations, and Future Work

5.1

Conclusions
Many clinical therapies could benefit from an in vitro protocol of generating

hematopoietic cells in a reproducible manner. Methods to produce both HSCs and
megakaryocytes, and subsequently platelets, would greatly advance treatment of
hematopoietic diseases.

Additionally, these protocols could allow further study of

hematopoiesis during human development. Many hematopoietic differentiation protocols
have been published. However, only a small portion of these are feeder-free and serumfree, thus allowing clinical translation. Even fewer allow for target cells to be harvested
in bulk, and none present an efficient method of producing primitive erythromyeloid
progenitors and megakaryocytes. We have created a high throughput assay capable of
optimizing EB based differentiation of hESCs toward one of the three primary germ
layers, and applied this assay to create a stepwise serum-free, feeder-free protocol for the
highly efficient generation of CD41+CD235+ erythromyeloid progenitors and
CD41+CD42a+ megakaryocytes.
We have shown that the 4-color differentiation assay itself can distinguish
between the three primary germ layers and from undifferentiated pluripotent stem cells
using the 4 markers as described. Differentiation toward any lineage could potentially be
examined by selection of the proper combination of biomarkers. The use of 4 colors is
determined by the technical capability of the flow cytometer.

At this point, no

commercially available instruments exist that allow 96-well plate flow cytometry and are
capable of more colors. This is likely to be overcome within several years. Naturally,
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more colors would allow for more markers to be assessed, allowing for greater cell
specification and more elaborate experiments.

At least one 384-well plate flow

cytometer is available. However, at this point, in our opinion, EB differentiation within a
384-well plate would not be possible. Cell counts would be too low to allow for reliable
differentiation and accurate analysis.
To our knowledge, two other groups have created small-scale differentiation
optimization assays [23, 26]. Both of these rely upon culturing single EBs within 96-well
plates.

This allows for precise experiments upon culture conditions and signaling

pathways to be performed. Both methods also ensure uniform EB size. However, hESCs
undoubtedly release factors into surrounding medium during differentiation. This crosstalk between EBs most assuredly would have effects upon differentiation progress,
course, or efficiency. Neither method is directly scalable to larger platforms, which
limits the ability to design a system to supply hematopoietic cells for clinical purposes.
Our system accomplishes both of these goals. We have shown scalability to 6-well
culture for hematopoietic differentiation.
staining

and

flow

cytometry

This system also allows highly efficient

without

the

need

to

pool

cells.

We have defined a primitive hematopoietic EB differentiation protocol using
stepwise addition of defined differentiation media at specified stages. By inhibiting
GSK-3b through the supplementation of Chir-99021, we observed differentiation yields
of over 80% for Day 3 KDR+ cells, over 70% for day 5 KDR+CD31+ cells, and over 25%
for day 8 CD43+ CD41+CD235+ primitive progenitors. We then performed a screen of all
combinations of four cytokines to enhance day 8 and day 11 CD43+ yields to
approximately 64% and 104%, respectively. In summary, we obtained yields of about
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two CD41+CD235+ primitive hematopoietic progenitors and one CD41+CD42+
megakaryocyte for every hESC plated.

5.2

Limitations & pitfalls
As with all techniques, this differentiation assay has advantages and

disadvantages. It is relevant to highlight the limitations in order to properly interpret
results and design future experiments accordingly.

5.2.1 Flow cytometry
This protocol relies upon a commercially available 96-well flow cytometry unit.
As previously discussed, only four markers can be assessed simultaneously, limiting the
conclusions that can be drawn from a single sample. Furthermore, if markers are only
expressed transiently, then a given marker combination will only be applicable for a brief
period of time.

This places limitations on abilities to accurately detect complex

arrangements of differentiation kinematics. For ectoderm detection, a NCAM+/SSEA3+
identity was utililized.

This is clearly transient as SSEA3 is only expressed within early

ectoderm. Thus, if a given condition enhances ectoderm differentiation by quickening its
pace, the observer may be oblivious due to absence of SSEA3 expression. If more than
four colors are desirable, multiple samples must be run and stained separately. Protocols
exist for assessing 5 colors simultaneously from a 4 color system, but these were never
tried.
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Generally, it would require 60-90 minutes to read an entire 96-well plate.
Consequently, some samples would be analyzed 90 minutes apart. Given the small
volume, this creates concerns for sample temperature, evaporation, viability, and
potential differentiation. Additionally, cells would easily settle during this time, ensuring
the need for frequent plate agitation. In order to minimize these confounding variables,
plates were covered with a lid and kept on ice after staining.

Columns would be

transferred to a new 96-well round bottom plate one at a time and acquired immediately.
Round bottom plates were utilized because, according to the manufacturer’s instructions,
V-bottom plates are not accurate for absolute cell counts. If only a few columns were
needed, plate transfer would not be performed, but wells would be agitated by trituration
with a pipet multichannel just prior to acquisition.

5.2.2 EB dissociation
In order to perform accurate flow cytometry, EBs must be dissociated to single
cells. In many standard 6-well culture protocols, then entails enzymatic cleavage of
cellular bonds followed by rigorous trituration with a syringe and needle. A 96-well plate
system renders this single sample technique impractical. Hence, EB dissociation is all
the more difficult. For early stage EBs (less than 7-8 days), 0.25% trypsin-EDTA will
suffice for dissociation. For larger, later stage EBs, a collagenase incubation period must
be performed initially, followed by incubation with a harsher agent (such as trypsin). We
have observed two caveats that arise from either of these dissociation options.
First, some antigens, such as CD41, are especially to trypsin and will be cleaved
off within several minutes. This can easily confound results if not expected. Second, if
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EBs are not completely dissociated, flow cytometer occlusion will likely occur.
Additionally, cells within EBs will not be analyzed. If samples mixed with EBs and
single cells are dissociated together, this will give a reading that 100% of cells in the
sample are single cells and artificially inflating differentiation efficiency. The latter is
also true if EBs are improperly enzymatically dissociated and too rigoursly mechanically
separated, resulting in cell death. Thus, trial experiments should be performed to test
antigen sensitivity to the applied dissociation agent. For hematopoietic experiments, we
found that incubation of cells with Collagenase B for one hour at 37ºC, followed by 5-15
minutes of accutase incubation at 37ºC with occasional trituration would generally
suffice. EBs should be examined with a microscope to ensure disruption.

5.3

Future work

5.3.1 Hematopoietic differentiation
We utilized flow cytometry to characterize cell populations capable of
multilineage primitive hematopoietic potential. As a first more thorough assessment of
the identity of these cells, transcript expression analysis should be performed. Chir99021 supplementation generated quicker differentiation of KDR+ mesoderm cells.
Brachyury expression should be monitored in the first 3 days to assess the effect of Chir
upon differentiation to the primitive streak. Throughout the differentiation process, gene
expression should be evaluated to verify lineage commitment. Genes to be evaluated
include: SCL (hematopoietic commitment), LMO2 (hematopoietic commitment, erythromegakaryocytic

specification),

RUNX1

(hematopoietic

commitment,

definitive
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hematopoietic potential), C-MYB (definitive hematopoietic potential, lymphomyeloid
lineages), GATA2 (hematopoietic commitment), GATA1 (erythro-megakaryocytic
specification) [89], the megakaryocyte specific genes MPL, FLI1, and the erythrocytic
specific genes EPOR and KLF1 [86].
In order to further understand the mechanism behind Chir-induced enhancement,
experiments should be performed to verify that b-catenin phosphorylation is prevented
and that nuclear translocation occurs.

First, b -catenin phosphorylation could be

evaluated by staining with a p-b-catenin specific antibody. Nuclear translocation can be
verified by immunofluorescence staining of hESCs 24 hours after Chir supplementation.
B-catenin functionality can be evaluated by evaluating the subsequent activation of
downstream genes, such as SP5 or AXIN2 [111]. Enhanced proliferation after Chir
supplementation could be assessed by evaluating BrdU incorporation.

Decreased

apoptosis could be evaluated by using TUNEL analysis. Furthermore, colony potential of
hematopoietic progenitors produced following Chir supplementation should be evaluated.
By screening 4 hematopoietic cytokines, we drastically increased the yield of
progenitors and megakaryocytes.

This yield could likely be increased further by

screening other commonly utilized cytokines. A first screen should evaluate EPO and
SCF. We observed IL-6 to potentially decrease megakaryocyte specification. Thus, FP6,
a soluble form of the IL-6 receptor, could be added to remove any soluble IL-6 [112].
Additionally, the Notch ligand Delta-like1 (DL-1) has been demonstrated to induce
megakaryopoiesis from adult HSCs [113]. It would be interesting to conduct a screen
with recombinant IL-6. While trends identified by the hematopoietic cytokine screen
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were consistent and convincing, conclusions drawn from screens should be interpreted
cautiously. Future studies will involve follow-up and further validation of these results.
Due to the fact that megakaryocytes are difficult to detect in standard
methycellulose cultures such as that used here, a megakaryocyte-specific culture assay
(MegaCult, StemCell Technologies) could be utilized. Additionally, in order to assess
functionality, fibrin clot assays should be performed upon harvested megakaryocytes
[86].

5.3.2 Differentiation assay
By utilization of fluorescent or luminescent reporter genes, this culture system
could be adapted to endstage readouts other than flow cytometry. For instance, by using
Gadue et al.’s Brachyury-driven GFP system, we could perform screens to assess effect
upon differentiation to the primitive streak [9]. Promoter-specific luciferase cell lines
would offer the ability to lyse cells and perform efficient viability and luciferase
measurements by utilization of a plate reader.

90

6.

References

[1] J.A. Thomson, J. Itskovitz-Eldor, S.S. Shapiro, M.A. Waknitz, J.J. Swiergiel, V.S.
Marshall, J.M. Jones, Embryonic stem cell lines derived from human blastocysts,
Science, 282 (1998) 1145-1147.
[2] J. Itskovitz-Eldor, M. Schuldiner, D. Karsenti, A. Eden, O. Yanuka, M. Amit, H.
Soreq, N. Benvenisty, Differentiation of human embryonic stem cells into embryoid
bodies compromising the three embryonic germ layers, Molecular Medicine, 6 (2000) 8895.
[3] B.E. Reubinoff, M.F. Pera, C.Y. Fong, A. Trounson, A. Bongso, Embryonic stem cell
lines from human blastocysts: somatic differentiation in vitro, Nat Biotechnol, 18 (2000)
399-404.
[4] J.G. Chenoweth, R.D. McKay, P.J. Tesar, Epiblast stem cells contribute new insight
into pluripotency and gastrulation, Dev Growth Differ, 52 293-301.
[5] P. Gadue, T.L. Huber, M.C. Nostro, S. Kattman, G.M. Keller, Germ layer induction
from embryonic stem cells, Experimental Hematology, 33 (2005) 955-964.
[6] C.E. Murry, G. Keller, Differentiation of embryonic stem cells to clinically relevant
populations: lessons from embryonic development, Cell, 132 (2008) 661-680.
[7] H. Kurosawa, Methods for inducing embryoid body formation: in vitro differentiation
system of embryonic stem cells, Journal of Bioscience & Bioengineering, 103 (2007)
389-398.

91

[8] T. Yamada, M. Yoshikawa, S. Kanda, Y. Kato, Y. Nakajima, S. Ishizaka, Y. Tsunoda,
In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by
cellular uptake of indocyanine green, Stem Cells, 20 (2002) 146-154.
[9] P. Gadue, T.L. Huber, P.J. Paddison, G.M. Keller, Wnt and TGF-beta signaling are
required for the induction of an in vitro model of primitive streak formation using
embryonic stem cells, Proceedings of the National Academy of Sciences of the United
States of America, 103 (2006) 16806-16811.
[10] S.M. Dang, M. Kyba, R. Perlingeiro, G.Q. Daley, P.W. Zandstra, Efficiency of
embryoid body formation and hematopoietic development from embryonic stem cells in
different culture systems, Biotechnology & Bioengineering, 78 (2002) 442-453.
[11] R.L. Carpenedo, C.Y. Sargent, T.C. McDevitt, Rotary suspension culture enhances
the efficiency, yield, and homogeneity of embryoid body differentiation, Stem Cells, 25
(2007) 2224-2234.
[12] M.D. Ungrin, C. Joshi, A. Nica, C. Bauwens, P.W. Zandstra, Reproducible, ultra
high-throughput formation of multicellular organization from single cell suspensionderived human embryonic stem cell aggregates, PLoS ONE [Electronic Resource], 3
(2008) e1565.
[13] M.V. Wiles, G. Keller, Multiple hematopoietic lineages develop from embryonic
stem (ES) cells in culture, Development, 111 (1991) 259-267.
[14] B.C. Zandstra PW, Yin T, Liu Q, Schiller H, Zweigerdt R, Pasumarthi KB, Field
LJ., Scalable production of embryonic stem cell-derived cardiomyocytes, Tissue
Engineering, 9 (2003) 767-778.

92

[15] I. Orlovskaya, I. Schraufstatter, J. Loring, S. Khaldoyanidi, Hematopoietic
differentiation of embryonic stem cells, Methods, 45 (2008) 159-167.
[16] K.A. D'Amour, A.G. Bang, S. Eliazer, O.G. Kelly, A.D. Agulnick, N.G. Smart,
M.A. Moorman, E. Kroon, M.K. Carpenter, E.E. Baetge, Production of pancreatic
hormone-expressing endocrine cells from human embryonic stem cells, Nature
Biotechnology, 24 (2006) 1392-1401.
[17] M. Kyba, R.C. Perlingeiro, G.Q. Daley, HoxB4 confers definitive lymphoid-myeloid
engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors,
Cell, 109 (2002) 29-37.
[18] E.T. Zambidis, B. Peault, T.S. Park, F. Bunz, C.I. Civin, Hematopoietic
differentiation of human embryonic stem cells progresses through sequential
hematoendothelial, primitive, and definitive stages resembling human yolk sac
development, Blood, 106 (2005) 860-870.
[19] M. Kennedy, S.L. D'Souza, M. Lynch-Kattman, S. Schwantz, G. Keller,
Development of the hemangioblast defines the onset of hematopoiesis in human ES cell
differentiation cultures, Blood, 109 (2007) 2679-2687.
[20] K. Matsumoto, T. Isagawa, T. Nishimura, T. Ogaeri, K. Eto, S. Miyazaki, J.
Miyazaki, H. Aburatani, H. Nakauchi, H. Ema, Stepwise development of hematopoietic
stem cells from embryonic stem cells, PLoS One, 4 (2009) e4820.
[21] M. Nakanishi, A. Kurisaki, Y. Hayashi, M. Warashina, S. Ishiura, M. Kusuda-Furue,
M. Asashima, Directed induction of anterior and posterior primitive streak by Wnt from
embryonic stem cells cultured in a chemically defined serum-free medium, FASEB
Journal, 23 (2009) 114-122.
93

[22] E.S. Ng, R. Davis, E.G. Stanley, A.G. Elefanty, A protocol describing the use of a
recombinant protein-based, animal product-free medium (APEL) for human embryonic
stem cell differentiation as spin embryoid bodies, Nat Protoc, 3 (2008) 768-776.
[23] E.S. Ng, R.P. Davis, L. Azzola, E.G. Stanley, A.G. Elefanty, Forced aggregation of
defined numbers of human embryonic stem cells into embryoid bodies fosters robust,
reproducible hematopoietic differentiation, Blood, 106 (2005) 1601-1603.
[24] M. Pick, L. Azzola, A. Mossman, E.G. Stanley, A.G. Elefanty, Differentiation of
human embryonic stem cells in serum-free medium reveals distinct roles for bone
morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and
fibroblast growth factor 2 in hematopoiesis, Stem Cells, 25 (2007) 2206-2214.
[25] R.P. Davis, E.S. Ng, M. Costa, A.K. Mossman, K. Sourris, A.G. Elefanty, E.G.
Stanley, Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem
cells identifies human primitive streak-like cells and enables isolation of primitive
hematopoietic precursors, Blood, 111 (2008) 1876-1884.
[26] M. Koike, H. Kurosawa, Y. Amano, A Round-bottom 96-well Polystyrene Plate
Coated with 2-methacryloyloxyethyl Phosphorylcholine as an Effective Tool for
Embryoid Body Formation, Cytotechnology, 47 (2005) 3-10.
[27] M. Koike, S. Sakaki, Y. Amano, H. Kurosawa, Characterization of embryoid bodies
of mouse embryonic stem cells formed under various culture conditions and estimation of
differentiation status of such bodies, J Biosci Bioeng, 104 (2007) 294-299.
[28] M. Borowiak, R. Maehr, S. Chen, A.E. Chen, W. Tang, J.L. Fox, S.L. Schreiber,
D.A. Melton, Small molecules efficiently direct endodermal differentiation of mouse and
human embryonic stem cells, Cell Stem Cell, 4 (2009) 348-358.
94

[29] S.C. Desbordes, D.G. Placantonakis, A. Ciro, N.D. Socci, G. Lee, H. Djaballah, L.
Studer, High-throughput screening assay for the identification of compounds regulating
self-renewal and differentiation in human embryonic stem cells, Cell Stem Cell, 2 (2008)
602-612.
[30] S. Irion, H. Luche, P. Gadue, H.J. Fehling, M. Kennedy, G. Keller, Identification
and targeting of the ROSA26 locus in human embryonic stem cells, Nat Biotechnol, 25
(2007) 1477-1482.
[31] J.T. Outten, P. Gadue, D.L. French, S.L. Diamond, High-throughput screening assay
for embryoid body differentiation of human embryonic stem cells, Curr Protoc Stem Cell
Biol, Chapter 1 (2012) Unit 1D 6.
[32] M. Zhao, H. Yang, X. Jiang, W. Zhou, B. Zhu, Y. Zeng, K. Yao, C. Ren,
Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic
stem cells, Mol Biotechnol, 40 (2008) 19-26.
[33] C. Park, I. Afrikanova, Y.S. Chung, W.J. Zhang, E. Arentson, G. Fong Gh, A.
Rosendahl, K. Choi, A hierarchical order of factors in the generation of FLK1- and SCLexpressing hematopoietic and endothelial progenitors from embryonic stem cells,
Development, 131 (2004) 2749-2762.
[34] L. Vallier, P.J. Rugg-Gunn, I.A. Bouhon, F.K. Andersson, A.J. Sadler, R.A.
Pedersen, Enhancing and diminishing gene function in human embryonic stem cells,
Stem Cells, 22 (2004) 2-11.
[35] D.C. Hay, L. Sutherland, J. Clark, T. Burdon, Oct-4 knockdown induces similar
patterns of endoderm and trophoblast differentiation markers in human and mouse
embryonic stem cells, Stem Cells, 22 (2004) 225-235.
95

[36] H. Zaehres, M.W. Lensch, L. Daheron, S.A. Stewart, J. Itskovitz-Eldor, G.Q. Daley,
High-efficiency RNA interference in human embryonic stem cells, Stem Cells, 23 (2005)
299-305.
[37] R.T. Rodriguez, J.M. Velkey, C. Lutzko, R. Seerke, D.B. Kohn, K.S. O'Shea, M.T.
Firpo, Manipulation of OCT4 levels in human embryonic stem cells results in induction
of differential cell types, Experimental Biology & Medicine, 232 (2007) 1368-1380.
[38] N. Izumi, T. Era, H. Akimaru, M. Yasunaga, S. Nishikawa, Dissecting the molecular
hierarchy for mesendoderm differentiation through a combination of embryonic stem cell
culture and RNA interference, Stem Cells, 25 (2007) 1664-1674.
[39] L. Yang, M.H. Soonpaa, E.D. Adler, T.K. Roepke, S.J. Kattman, M. Kennedy, E.
Henckaerts, K. Bonham, G.W. Abbott, R.M. Linden, L.J. Field, G.M. Keller, Human
cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived
population, Nature, 453 (2008) 524-528.
[40] M. Yasunaga, S. Tada, S. Torikai-Nishikawa, Y. Nakano, M. Okada, L.M. Jakt, S.
Nishikawa, T. Chiba, T. Era, S. Nishikawa, Induction and monitoring of definitive and
visceral endoderm differentiation of mouse ES cells, Nat Biotechnol, 23 (2005) 15421550.
[41] K.E. McGrath, A.D. Koniski, K.M. Maltby, J.K. McGann, J. Palis, Embryonic
expression and function of the chemokine SDF-1 and its receptor, CXCR4,
Developmental Biology, 213 (1999) 442-456.
[42] M.C. Nostro, X. Cheng, G.M. Keller, P. Gadue, Wnt, activin, and BMP signaling
regulate distinct stages in the developmental pathway from embryonic stem cells to
blood, Cell Stem Cell, 2 (2008) 60-71.
96

[43] H. Sakurai, T. Era, L.M. Jakt, M. Okada, S. Nakai, S. Nishikawa, S. Nishikawa, In
vitro modeling of paraxial and lateral mesoderm differentiation reveals early reversibility,
Stem Cells, 24 (2006) 575-586.
[44] T. Enver, S. Soneji, C. Joshi, J. Brown, F. Iborra, T. Orntoft, T. Thykjaer, E. Maltby,
K. Smith, R.A. Dawud, M. Jones, M. Matin, P. Gokhale, J. Draper, P.W. Andrews,
Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem
cells, Hum Mol Genet, 14 (2005) 3129-3140.
[45] R. Kannagi, N.A. Cochran, F. Ishigami, S. Hakomori, P.W. Andrews, B.B. Knowles,
D. Solter, Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique
globo-series ganglioside isolated from human teratocarcinoma cells, Embo J, 2 (1983)
2355-2361.
[46] J. Pruszak, K.C. Sonntag, M.H. Aung, R. Sanchez-Pernaute, O. Isacson, Markers
and methods for cell sorting of human embryonic stem cell-derived neural cell
populations, Stem Cells, 25 (2007) 2257-2268.
[47] I.H. Park, R. Zhao, J.A. West, A. Yabuuchi, H. Huo, T.A. Ince, P.H. Lerou, M.W.
Lensch, G.Q. Daley, Reprogramming of human somatic cells to pluripotency with
defined factors.[see comment], Nature, 451 (2008) 141-146.
[48] P.M. Lackie, C. Zuber, J. Roth, Polysialic acid of the neural cell adhesion molecule
(N-CAM) is widely expressed during organogenesis in mesodermal and endodermal
derivatives, Differentiation, 57 (1994) 119-131.
[49] C.J. Moller, S. Christgau, M.R. Williamson, O.D. Madsen, Z.P. Niu, E. Bock, S.
Baekkeskov, Differential expression of neural cell adhesion molecule and cadherins in

97

pancreatic islets, glucagonomas, and insulinomas, Molecular Endocrinology, 6 (1992)
1332-1342.
[50] S.M. Chambers, C.A. Fasano, E.P. Papapetrou, M. Tomishima, M. Sadelain, L.
Studer, Highly efficient neural conversion of human ES and iPS cells by dual inhibition
of SMAD signaling, Nat Biotechnol, 27 (2009) 275-280.
[51] L. Vallier, T. Touboul, Z. Chng, M. Brimpari, N. Hannan, E. Millan, L.E. Smithers,
M. Trotter, P. Rugg-Gunn, A. Weber, R.A. Pedersen, Early cell fate decisions of human
embryonic stem cells and mouse epiblast stem cells are controlled by the same signalling
pathways, PLoS One, 4 (2009) e6082.
[52] U. Lendahl, L.B. Zimmerman, R.D. McKay, CNS stem cells express a new class of
intermediate filament protein, Cell, 60 (1990) 585-595.
[53] H.J. Fehling, G. Lacaud, A. Kubo, M. Kennedy, S. Robertson, G. Keller, V.
Kouskoff, Tracking mesoderm induction and its specification to the hemangioblast
during embryonic stem cell differentiation, Development, 130 (2003) 4217-4227.
[54] Y. Wang, N. Nakayama, WNT and BMP signaling are both required for
hematopoietic cell development from human ES cells, Stem Cell Res, 3 (2009) 113-125.
[55] S. Tada, T. Era, C. Furusawa, H. Sakurai, S. Nishikawa, M. Kinoshita, K. Nakao, T.
Chiba, S. Nishikawa, Characterization of mesendoderm: a diverging point of the
definitive endoderm and mesoderm in embryonic stem cell differentiation culture,
Development, 132 (2005) 4363-4374.
[56] L.G. Chase, M.T. Firpo, Development of serum-free culture systems for human
embryonic stem cells, Current Opinion in Chemical Biology, 11 (2007) 367-372.

98

[57] K. Tachibana, S. Hirota, H. Iizasa, H. Yoshida, K. Kawabata, Y. Kataoka, Y.
Kitamura, K. Matsushima, N. Yoshida, S. Nishikawa, T. Kishimoto, T. Nagasawa, The
chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract,
Nature, 393 (1998) 591-594.
[58] J. Imitola, K. Raddassi, K.I. Park, F.J. Mueller, M. Nieto, Y.D. Teng, D. Frenkel, J.
Li, R.L. Sidman, C.A. Walsh, E.Y. Snyder, S.J. Khoury, Directed migration of neural
stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC
chemokine receptor 4 pathway, Proc Natl Acad Sci U S A, 101 (2004) 18117-18122.
[59] M. Ema, S. Takahashi, J. Rossant, Deletion of the selection cassette, but not cisacting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent
mesodermal progenitors, Blood, 107 (2006) 111-117.
[60] S.J. Kattman, T.L. Huber, G.M. Keller, Multipotent flk-1+ cardiovascular progenitor
cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages,
Dev Cell, 11 (2006) 723-732.
[61] F.W. King, C. Ritner, W. Liszewski, H.C. Kwan, A. Pedersen, A.D. Leavitt, H.S.
Bernstein, Subpopulations of human embryonic stem cells with distinct tissue-specific
fates can be selected from pluripotent cultures, Stem Cells Dev, 18 (2009) 1441-1450.
[62] M. Nakagawa, M. Koyanagi, K. Tanabe, K. Takahashi, T. Ichisaka, T. Aoi, K.
Okita, Y. Mochiduki, N. Takizawa, S. Yamanaka, Generation of induced pluripotent stem
cells without Myc from mouse and human fibroblasts, Nat Biotechnol, 26 (2008) 101106.

99

[63] B. Parekkadan, Y. Berdichevsky, D. Irimia, A. Leeder, G. Yarmush, M. Toner, J.B.
Levine, M.L. Yarmush, Cell-cell interaction modulates neuroectodermal specification of
embryonic stem cells, Neuroscience Letters, 438 (2008) 190-195.
[64] J.R. Smith, L. Vallier, G. Lupo, M. Alexander, W.A. Harris, R.A. Pedersen,
Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem
cells into neuroectoderm, Developmental Biology, 313 (2008) 107-117.
[65] K. Watanabe, D. Kamiya, A. Nishiyama, T. Katayama, S. Nozaki, H. Kawasaki, Y.
Watanabe, K. Mizuseki, Y. Sasai, Directed differentiation of telencephalic precursors
from embryonic stem cells, Nature Neuroscience, 8 (2005) 288-296.
[66] M.T. Pankratz, X.J. Li, T.M. Lavaute, E.A. Lyons, X. Chen, S.C. Zhang, Directed
neural differentiation of human embryonic stem cells via an obligated primitive anterior
stage, Stem Cells, 25 (2007) 1511-1520.
[67] K.A. D'Amour, A.D. Agulnick, S. Eliazer, O.G. Kelly, E. Kroon, E.E. Baetge,
Efficient differentiation of human embryonic stem cells to definitive endoderm, Nature
Biotechnology, 23 (2005) 1534-1541.
[68] O. Goldman, O. Feraud, J. Boyer-Di Ponio, C. Driancourt, D. Clay, M.C. Le
Bousse-Kerdiles, A. Bennaceur-Griscelli, G. Uzan, A boost of BMP4 accelerates the
commitment of human embryonic stem cells to the endothelial lineage, Stem Cells, 27
(2009) 1750-1759.
[69] P. Zhang, J. Li, Z. Tan, C. Wang, T. Liu, L. Chen, J. Yong, W. Jiang, X. Sun, L. Du,
M. Ding, H. Deng, Short-term BMP-4 treatment initiates mesoderm induction in human
embryonic stem cells, Blood, 111 (2008) 1933-1941.

100

[70] R. Patani, A. Compston, C.A. Puddifoot, D.J. Wyllie, G.E. Hardingham, N.D. Allen,
S. Chandran, Activin/Nodal inhibition alone accelerates highly efficient neural
conversion from human embryonic stem cells and imposes a caudal positional identity,
PLoS ONE [Electronic Resource], 4 (2009) e7327.
[71] S. Armknecht, M. Boutros, A. Kiger, K. Nybakken, B. Mathey-Prevot, N. Perrimon,
High-throughput RNA interference screens in Drosophila tissue culture cells, Methods
Enzymol, 392 (2005) 55-73.
[72] G.A. Barker, S.L. Diamond, RNA interference screen to identify pathways that
enhance or reduce nonviral gene transfer during lipofection, Mol Ther, 16 (2008) 16021608.
[73] H.M. Faessel, L.M. Levasseur, H.K. Slocum, W.R. Greco, Parabolic growth patterns
in 96-well plate cell growth experiments, In Vitro Cell Dev Biol Anim, 35 (1999) 270278.
[74] E. Lucumi, C. Darling, H. Jo, A.D. Napper, R. Chandramohanadas, N. Fisher, A.E.
Shone, H. Jing, S.A. Ward, G.A. Biagini, W.F. DeGrado, S.L. Diamond, D.C.
Greenbaum, Discovery of potent small-molecule inhibitors of multidrug-resistant
Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based
assay, Antimicrob Agents Chemother, 54 3597-3604.
[75] Y. Xu, S.H. Mirmalek-Sani, F. Lin, J. Zhang, R.O. Oreffo, Adipocyte differentiation
induced using nonspecific siRNA controls in cultured human mesenchymal stem cells,
Rna, 13 (2007) 1179-1183.
[76] S. Yao, S. Chen, J. Clark, E. Hao, G.M. Beattie, A. Hayek, S. Ding, Long-term selfrenewal and directed differentiation of human embryonic stem cells in chemically
101

defined conditions, Proceedings of the National Academy of Sciences of the United
States of America, 103 (2006) 6907-6912.
[77] L. Xiao, X. Yuan, S.J. Sharkis, Activin A maintains self-renewal and regulates
fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human
embryonic stem cells, Stem Cells, 24 (2006) 1476-1486.
[78] H. Bai, Y. Gao, M. Arzigian, D.M. Wojchowski, W.S. Wu, Z.Z. Wang, BMP4
regulates vascular progenitor development in human embryonic stem cells through a
smad-dependent pathway, J Cell Biochem, 109 363-374.
[79] G. Narazaki, H. Uosaki, M. Teranishi, K. Okita, B. Kim, S. Matsuoka, S. Yamanaka,
J.K. Yamashita, Directed and systematic differentiation of cardiovascular cells from
mouse induced pluripotent stem cells, Circulation, 118 (2008) 498-506.
[80] J. Palis, S. Robertson, M. Kennedy, C. Wall, G. Keller, Development of erythroid
and myeloid progenitors in the yolk sac and embryo proper of the mouse, Development,
126 (1999) 5073-5084.
[81] J.C. Boisset, C. Robin, On the origin of hematopoietic stem cells: progress and
controversy, Stem Cell Res, 8 (2012) 1-13.
[82] T.L. Huber, V. Kouskoff, H.J. Fehling, J. Palis, G. Keller, Haemangioblast
commitment is initiated in the primitive streak of the mouse embryo, Nature, 432 (2004)
625-630.
[83] J. Tober, A. Koniski, K.E. McGrath, R. Vemishetti, R. Emerson, K.K. de MesyBentley, R. Waugh, J. Palis, The megakaryocyte lineage originates from hemangioblast
precursors and is an integral component both of primitive and of definitive
hematopoiesis, Blood, 109 (2007) 1433-1441.
102

[84] I. Godin, F. Dieterlen-Lievre, A. Cumano, Emergence of multipotent hemopoietic
cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5
days postcoitus, Proc Natl Acad Sci U S A, 92 (1995) 773-777.
[85] A. Medvinsky, E. Dzierzak, Definitive hematopoiesis is autonomously initiated by
the AGM region, Cell, 86 (1996) 897-906.
[86] O. Klimchenko, M. Mori, A. Distefano, T. Langlois, F. Larbret, Y. Lecluse, O.
Feraud, W. Vainchenker, F. Norol, N. Debili, A common bipotent progenitor generates
the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive
hematopoiesis, Blood, 114 (2009) 1506-1517.
[87] T. Nakano, H. Kodama, T. Honjo, Generation of lymphohematopoietic cells from
embryonic stem cells in culture, Science, 265 (1994) 1098-1101.
[88] M.A. Vodyanik, J.A. Bork, J.A. Thomson, Slukvin, II, Human embryonic stem cellderived CD34+ cells: efficient production in the coculture with OP9 stromal cells and
analysis of lymphohematopoietic potential, Blood, 105 (2005) 617-626.
[89] M.A. Vodyanik, J.A. Thomson, Slukvin, II, Leukosialin (CD43) defines
hematopoietic progenitors in human embryonic stem cell differentiation cultures, Blood,
108 (2006) 2095-2105.
[90] L. Chicha, A. Feki, A. Boni, O. Irion, O. Hovatta, M. Jaconi, Human pluripotent
stem cells differentiated in fully defined medium generate hematopoietic CD34- and
CD34+ progenitors with distinct characteristics, PLoS One, 6 (2011) e14733.
[91] A. Niwa, T. Heike, K. Umeda, K. Oshima, I. Kato, H. Sakai, H. Suemori, T.
Nakahata, M.K. Saito, A novel serum-free monolayer culture for orderly hematopoietic

103

differentiation of human pluripotent cells via mesodermal progenitors, PLoS ONE
[Electronic Resource], 6 (2011) e22261.
[92] J.T. Outten, X. Cheng, P. Gadue, D.L. French, S.L. Diamond, A high-throughput
multiplexed screening assay for optimizing serum-free differentiation protocols of human
embryonic stem cells, Stem Cell Res, 6 (2011) 129-142.
[93] S.R. Braam, R. Nauw, D. Ward-van Oostwaard, C. Mummery, R. Passier, Inhibition
of ROCK improves survival of human embryonic stem cell-derived cardiomyocytes after
dissociation, Ann N Y Acad Sci, 1188 (2010) 52-57.
[94] R.C. Lindsley, J.G. Gill, M. Kyba, T.L. Murphy, K.M. Murphy, Canonical Wnt
signaling is required for development of embryonic stem cell-derived mesoderm,
Development, 133 (2006) 3787-3796.
[95] L.G. Villa-Diaz, C. Pacut, N.A. Slawny, J. Ding, K.S. O'Shea, G.D. Smith, Analysis
of the factors that limit the ability of feeder cells to maintain the undifferentiated state of
human embryonic stem cells, Stem Cells Dev, 18 (2009) 641-651.
[96] E.H. Lee, R. Chari, A. Lam, R.T. Ng, J. Yee, J. English, K.G. Evans, C. Macaulay,
S. Lam, W.L. Lam, Disruption of the non-canonical WNT pathway in lung squamous cell
carcinoma, Clin Med Oncol, 2008 (2008) 169-179.
[97] M. Radinger, D. Smrz, D.D. Metcalfe, A.M. Gilfillan, Glycogen synthase kinase3beta is a prosurvival signal for the maintenance of human mast cell homeostasis, J
Immunol, 187 (2011) 5587-5595.
[98] D. Metcalf, L. Di Rago, S. Mifsud, Synergistic and inhibitory interactions in the in
vitro control of murine megakaryocyte colony formation, Stem Cells, 20 (2002) 552-560.

104

[99] M. Yu, A.B. Cantor, Megakaryopoiesis and thrombopoiesis: an update on cytokines
and lineage surface markers, Methods Mol Biol, 788 (2012) 291-303.
[100] S.J. Lu, Q. Feng, S. Caballero, Y. Chen, M.A. Moore, M.B. Grant, R. Lanza,
Generation of functional hemangioblasts from human embryonic stem cells, Nat
Methods, 4 (2007) 501-509.
[101] C. Lengerke, S. Schmitt, T.V. Bowman, I.H. Jang, L. Maouche-Chretien, S.
McKinney-Freeman, A.J. Davidson, M. Hammerschmidt, F. Rentzsch, J.B. Green, L.I.
Zon, G.Q. Daley, BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox
pathway, Cell Stem Cell, 2 (2008) 72-82.
[102] S. Ueno, G. Weidinger, T. Osugi, A.D. Kohn, J.L. Golob, L. Pabon, H. Reinecke,
R.T. Moon, C.E. Murry, Biphasic role for Wnt/beta-catenin signaling in cardiac
specification in zebrafish and embryonic stem cells, Proc Natl Acad Sci U S A, 104
(2007) 9685-9690.
[103] Y. Wang, K. Umeda, N. Nakayama, Collaboration between WNT and BMP
signaling promotes hemoangiogenic cell development from human fibroblast-derived iPS
cells, Stem Cell Res, 4 223-231.
[104] P.S. Woll, J.K. Morris, M.S. Painschab, R.K. Marcus, A.D. Kohn, T.L. Biechele,
R.T. Moon, D.S. Kaufman, Wnt signaling promotes hematoendothelial cell development
from human embryonic stem cells, Blood, 111 (2008) 122-131.
[105] K. Gauthaman, C.Y. Fong, A. Bongso, Effect of ROCK inhibitor Y-27632 on
normal and variant human embryonic stem cells (hESCs) in vitro: its benefits in hESC
expansion, Stem Cell Rev, 6 (2010) 86-95.

105

[106] C. Bueno, R. Montes, P. Menendez, The ROCK inhibitor Y-27632 negatively
affects the expansion/survival of both fresh and cryopreserved cord blood-derived CD34+
hematopoietic progenitor cells: Y-27632 negatively affects the expansion/survival of
CD34+HSPCs, Stem Cell Rev, 6 (2010) 215-223.
[107] S. Pearson, P. Sroczynska, G. Lacaud, V. Kouskoff, The stepwise specification of
embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4,
activin A, bFGF and VEGF, Development, 135 (2008) 1525-1535.
[108] E.T. Zambidis, T.S. Park, W. Yu, A. Tam, M. Levine, X. Yuan, M. Pryzhkova, B.
Peault, Expression of angiotensin-converting enzyme (CD143) identifies and regulates
primitive hemangioblasts derived from human pluripotent stem cells, Blood, 112 (2008)
3601-3614.
[109] M.G. Manz, T. Miyamoto, K. Akashi, I.L. Weissman, Prospective isolation of
human clonogenic common myeloid progenitors, Proc Natl Acad Sci U S A, 99 (2002)
11872-11877.
[110] A.E. Grigoriadis, M. Kennedy, A. Bozec, F. Brunton, G. Stenbeck, I.H. Park, E.F.
Wagner, G.M. Keller, Directed differentiation of hematopoietic precursors and functional
osteoclasts from human ES and iPS cells, Blood, 115 (2010) 2769-2776.
[111] M. Takahashi, Y. Nakamura, K. Obama, Y. Furukawa, Identification of SP5 as a
downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human
colon cancer, Int J Oncol, 27 (2005) 1483-1487.
[112] Y. Yokoyama, T. Suzuki, M. Sakata-Yanagimoto, K. Kumano, K. Higashi, T.
Takato, M. Kurokawa, S. Ogawa, S. Chiba, Derivation of functional mature neutrophils
from human embryonic stem cells, Blood, 113 (2009) 6584-6592.
106

[113] T. Mercher, M.G. Cornejo, C. Sears, T. Kindler, S.A. Moore, I. Maillard, W.S.
Pear, J.C. Aster, D.G. Gilliland, Notch signaling specifies megakaryocyte development
from hematopoietic stem cells, Cell Stem Cell, 3 (2008) 314-326.

107

